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Executive Summary 
Introduction 
Health problem 
This systematic review is focussed on patients with post-meniscectomy syn-
drome. A meniscus is a crescent-shaped piece of cartilage in the knee that 
provides load distribution, shock absorption and lubrication between the thigh 
(femur) and shin (tibia) bones. Post-meniscectomy syndrome is broadly char-
acterised by intractable pain following the partial or total removal of a me-
niscus. Removal of a meniscus can lead to joint instability, increased risk of 
osteoarthritis, and eventually total joint replacement.  
Description of technology 
Meniscal allograft transplantation (MAT) involves the transplant of a cadaver-
ic meniscal allograft into the knee of a patient who has had a prior (sub)total 
meniscectomy. The transplanted allograft is intended to be permanent, and 
aims to restore the load bearing and shock absorption function provided by 
the meniscus. In theory, MAT is proposed to relieve the pain and swelling 
associated with post-meniscectomy syndrome, lower the risk of progression 
to osteoarthritis, and prolong the need for a total knee replacement and as-
sociated revisions. 
In the absence of a clear surgical alternative to MAT in post-meniscectomy 
patients, conservative management is proposed as the main treatment alter-
native. There are no clear guidelines for what constitutes conservative man-
agement in the context of post-meniscectomy syndrome; however, the main 
treatment aims of conservative management include symptom control via an-
algesics and injections, stabilisation of the joint via muscle strengthening, 
and behaviour modification. 
Research question 
In patients with post-meniscectomy syndrome, is meniscus allograft trans-
plantation more effective concerning changes in pain, changes in function, 
and necessity of total joint replacement, and as safe concerning complications 
and transplant failure in comparison to conservative management? 
 
Methods 
The research question was investigated through a systematic review of the 
current literature on MAT. Four biomedical databases (Medline, Embase, the 
Cochrane Library, the University of York Centre for Reviews and Dissemina-
tion) were searched from inception to 22 December 2017. Two authors (TV, 
SF) independently conducted the study selection, data extraction, and quali-
ty appraisal. 
Domain effectiveness 
The outcomes used as evidence to derive a recommendation on the relative 
efficacy of MAT included: changes in pain scores (KOOS-Pain), changes in 
disease-specific function scores (IKDC, Lysholm, Tegner, KOOS), and the 
necessity for total knee arthroplasty (TKA). 
focus on patients with 
post-meniscectomy 
syndrome 
 
persistent pain after 
meniscectomy 
meniscal allograft 
transplantation (MAT) 
from cadaver, to relieve 
pain, lower risk of 
osteoarthritis 
conservative 
management is main 
treatment alternative 
meniscus allograft 
transplantation more 
effective and as safe? 
literature search in 
databases, selection, 
extraction, and quality 
appraisal by two authors 
pain, function,  
and necessity of  
knee arthroplasty  
for effectiveness 
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Domain safety 
The outcomes used as evidence to derive a recommendation on the relative 
safety of MAT included: procedure-related complications, and transplant fail-
ure. 
 
Results 
Available evidence 
Only one non-randomised comparative study with 36 patients was identified 
to derive a recommendation on the comparative effectiveness of MAT com-
pared to conservative management.  
In addition, five prospective case series with a total of 308 patients were in-
cluded in order to inform the recommendation on safety. 
Clinical effectiveness 
The change in patient-reported pain was significantly improved in the MAT 
group compared to conservative management at 12 months (MD 15.1, 95% 
CI 2.4 to 27.8, p=0.021). 
Regarding function, the mean difference in the change in scores was not sta-
tistically significant for Lysholm, IKDC or KOOS-Sports scores; however, 
KOOS-Composite and KOOS-ADL scores demonstrated significant increas-
es, favouring MAT. 
Quality of life demonstrated both clinically important and statistically sig-
nificant increases in the MAT group. 
Safety 
The relative risk of complications for MAT was 6.92 (95% CI 0.91 to 285.8, 
p>0.05) compared to conservative management. The overall complication 
rate for MAT across all studies was 22.9% (range 0.0% to 38.5%).  
All but one complication related to MAT required re-operation, typically with 
arthroscopy. No complications required re-intervention in the conservative 
management group. 
The overall failure rate of MAT was 4.6% (range 1.7% to 7.7%) with a mean 
follow-up time of 46 months (range 13 to 120). 
Upcoming evidence 
There are currently two registered clinical trials investigating MAT for the 
treatment of post-meniscectomy syndrome. Both trials are single arm studies 
(n=120 and 119), and as such will not provide additional certainty around 
the comparative efficacy of MAT in relation to conservative management. 
Reimbursement 
Currently, MAT is not reimbursed by the Austrian health care system for the 
treatment post-meniscectomy syndrome. 
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Discussion 
The overall quality of evidence identified for this review was very low for all 
of the reported outcomes.  
The main limitations in the evidence base were in relation to the level of ev-
idence (i.e. primarily case series), high risk of bias, and small sample sizes. 
In addition, interpreting the literature on MAT is complicated by the large 
number of concomitant procedures reported, varying techniques used to fix 
allografts, the number of prior procedures received by patients, poor report-
ing of complications, and the varied time-points at which outcomes were re-
ported. 
The current evidence is not sufficient to prove that MAT, for the treatment 
of post-meniscectomy syndrome, is more effective and equally safe than con-
servative management.  
 
Recommendation 
On the basis of the limited evidence demonstrating a benefit of MAT rela-
tive to the main comparator, as well as the lack of ongoing trials, inclusion 
in the hospital benefit catalogue is not recommended. 
 
 
  
very low  
quality of evidence 
no (proper) 
randomisation,  
high risk of bias,  
small sample sizes 
evidence not sufficient 
MAT not recommended 
for reimbursement 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Die vorliegende systematische Übersichtsarbeit konzentrierte sich auf Pati-
entInnen mit Postmeniskektomie-Syndrom. Ein Meniskus ist ein halbmond-
förmiges Knorpelstück im Knie, das eine Lastenverteilung, Stoßdämpfung 
und Schmierung zwischen den Knochen des Oberschenkels (Femur) und des 
Schienbeins (Tibia) gewährleistet. Das Postmeniskektomie-Syndrom ist weit-
gehend durch persistierende Schmerzen nach der teilweisen oder vollständi-
gen Entfernung eines Meniskus gekennzeichnet. Die Entfernung des Menis-
kus ist vorrangig bei inoperablen Rissen indiziert und kann zu Gelenkinsta-
bilität, erhöhtem Risiko für Osteoarthritis und schließlich zu totalem Ge-
lenkersatz führen. 
Beschreibung der Technologie 
Bei der Meniskustransplantation wird ein passender Spendermeniskus von 
verstorbenen Menschen in das Knie von PatientInnen eingesetzt, die zuvor 
einer (sub)totalen Meniskektomie unterzogen wurden. Der transplantierte 
Meniskus soll dauerhaft im Knie verbleiben und soll die vom Meniskus be-
reitgestellte Belastungs- und Stoßabsorptionsfunktion wiederherstellen. So 
soll eine Meniskustransplantation die, mit dem Postmeniskektomie-Syndrom 
verbundenen, Schmerzen und Schwellungen lindern, das Risiko einer mög-
lichen Gonarthrose verringern und die Notwendigkeit eines totalen Knieer-
satzes (Knieendoprothese) und damit einhergehende Revisionen vermeiden 
oder zumindest hinauszögern. 
Aufgrund einer fehlenden eindeutigen chirurgischen Alternative zur Menis-
kustransplantation bei Postmeniskektomie-PatientInnen wird eine konserva-
tive Behandlung als Hauptbehandlungsalternative vorgeschlagen. Jedoch gibt 
es keine klaren Richtlinien für die konkreten Inhalte eines konservativen Be-
handlungsansatzes im Rahmen des Postmeniskektomie-Syndroms. Die wich-
tigsten Behandlungsziele des konservativen Managements umfassen jedoch 
die Symptomkontrolle über Medikamente und Injektionen, die Stabilisierung 
des Gelenks durch Muskelstärkung (Physiotherapie) und Verhaltensmodifi-
kation. 
Wissenschaftliche Fragestellung 
Ist bei PatientInnen mit Postmeniskektomie-Syndrom die Meniskustrans-
plantation im Vergleich zu konservativem Management wirksamer bezüg-
lich Schmerzen, Funktion (des Kniegelenks) und der Notwendigkeit einer 
Knieendoprothese und zumindest gleich sicher im Hinblick auf Komplika-
tionen und Transplantatversagen? 
 
Methoden 
Zur Beantwortung der Forschungsfrage wurde am 22. Dezember 2017 eine 
systematische Literatursuche in vier Datenbanken (Medline, Embase, Coch-
rane Library, Center for Reviews and Dissemination of the University of York) 
durchgeführt. Zwei Autoren (TV, SF) führten unabhängig voneinander die 
Studienauswahl, Datenextraktion und Qualitätsbewertung durch. 
Fokus auf 
Postmeniskektomie-
Syndrom 
 
Entfernung Meniskus 
bei inoperablen Rissen, 
jedoch bleibende 
Schmerzen möglich 
Meniskustransplantation 
zur Schmerzreduktion 
und langfristig zur 
Vermeidung von 
Knieendoprothese 
konservative Therapie 
als vorrangige 
Behandlungsalternative 
Meniskustransplantation 
wirksamer und 
zumindest genauso 
sicher? 
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Klinische Wirksamkeit 
Die kritischen Endpunkte, die als Basis für eine Bewertung der Wirksamkeit 
der Meniskustransplantation herangezogen wurden, umfassten: Veränderun-
gen der Schmerzen (mittels KOOS-Pain), Veränderungen der krankheitsspe-
zifischen Funktion des Kniegelenks (mittels IKDC, Lysholm, Tegner, KOOS) 
und die Notwendigkeit einer totalen Knieendoprothese. 
Sicherheit 
Die Endpunkte, die für die Ableitung einer Empfehlung zur Sicherheit der 
Meniskustransplantation herangezogen wurden, umfassten: interventionsbe-
dingte Komplikationen und Versagen des Transplantates. 
 
Ergebnisse 
Verfügbare Evidenz 
Zur Bewertung der Wirksamkeit konnte lediglich eine nicht-randomisierte 
kontrollierte Studie mit 36 PatientInnen identifiziert werden, die die Menis-
kustransplantation mit einem konservativen Behandlungsansatz verglich. 
Zusätzlich konnten noch fünf prospektive Fallserien mit insgesamt 308 Pa-
tientInnen für die Bewertung der Sicherheit identifiziert werden. 
Klinische Wirksamkeit 
Die, von den PatientInnen berichteten, Schmerzen konnten 12 Monate nach 
dem Eingriff mittels Meniskustransplantation – im Vergleich zur konserva-
tiven Behandlung – signifikant verbessert werden (mittlere Differenz 15,1, 
95 % Konfidenzintervall 2,4 bis 27,8; p=0,021). 
Die Funktion (des Kniegelenks) konnte mittels Meniskustransplantation – 
im Vergleich zur konservativen Behandlungsmethode – nicht signifikant ver-
bessert werden, wenn diese mittels Lysholm, IKDC oder KOOS-Sport gemes-
sen wurden. Wurde die Funktion jedoch mit dem KOOS-Composite und dem 
KOOS-ADL (ADL steht für „activities of daily life“) gemessen, dann konnten 
signifikante Verbesserungen der Funktion mittels Meniskustransplantation 
festgestellt werden. 
Die Lebensqualität konnte mittels Meniskustransplantation sowohl klinisch 
relevant als auch statistisch signifikant verbessert werden – im Vergleich zur 
konservativen Therapie. 
Sicherheit 
Das relative Risiko für Komplikationen einer Meniskustransplantation, im 
Vergleich zur konservativen Therapie, lag bei 6,92 (95 % Konfidenzintervall 
von 0,91 bis 28,8; p>0,05). Die Komplikationsrate der Meniskustransplanta-
tion aller Studien lag durchschnittlich bei 22,9 % (in den einzelnen Studien 
lag die Rate zwischen 0 und 38,5 %). 
Mit Ausnahme einer Studie, bedurften alle, durch die Meniskustransplantati-
on bedingten, Komplikationen einer Reoperation, meist mittels Arthroskopie.  
Insgesamt versagten 4,6 % der Transplantate (in den einzelnen Studien lag 
die Rate zwischen 1,7 und 7,7 %), bei einer durchschnittlichen Nachbeobach-
tung von 46 Monaten. 
Wirksamkeitsendpunkte: 
Schmerzen, Funktion 
und Notwendigkeit 
Knieersatz 
Sicherheitsendpunkte: 
Komplikationen und 
Versagen Transplantat  
eine Vergleichsstudie 
mit 36 PatientInnen 
zusätzlich  
5 Fallserien  
Schmerzen: signifikante 
Verbesserung mit 
Meniskustransplantation 
Funktion:  
teilweise signifikante 
Verbesserungen mit  
Meniskustransplantation 
im Vergleich zu 
konservativer Therapie 
Lebensqualität: 
signifikante 
Verbesserungen mit  
Meniskustransplantation 
keine signifikanten 
Unterschiede bei 
Komplikationen 
fast alle Komplikationen 
bedurften Reoperation 
Transplantatsversagen 
in 4,6 % der Fälle 
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Laufende Studien 
Aktuell sind zwei laufende Studien registriert, die die Meniskustransplanta-
tion zur Behandlung des Postmeniskektomie-Syndroms untersuchen. Bei bei-
den Studien handelt es sich um unkontrollierte Fallserien (eine Studie mit 
120 und die andere mit 119 PatientInnen). Daher werden diese Studien kei-
ne neuen Erkenntnisse bezüglich der Wirksamkeit der Meniskustransplan-
tation im Vergleich zur konservativen Therapie liefern. 
Kostenerstattung 
Derzeit erfolgt keine Kostenerstattung der Meniskustransplantation zur Be-
handlung des Postmeniskektomie-Syndroms durch das öffentliche österrei-
chische Gesundheitssystem. 
 
Diskussion 
Insgesamt war die Qualität und Stärke der Evidenz, die für die Beantwortung 
der Forschungsfrage identifiziert wurde, sehr gering. 
Die Schwächen der Evidenz lagen vor allem im Design der Studien (z. B. 
handelte es sich Großteils um Fallserien), im hohen Bias-Risiko und in den 
kleinen Studiengrößen. Außerdem wurden die Komplikationen zum Teil un-
zureichend beschrieben und die Zeitpunkte der Outcome-Messung variierten 
mitunter erheblich, was die Vergleichbarkeit der Studienergebnisse stark 
beeinträchtigt. Darüber hinaus bleibt unklar, inwieweit die zahlreichen be-
gleitenden Interventionen (z. B. Kreuzbandplastiken), die verschiedenen OP-
Techniken zur Fixierung der Transplantate und die Anzahl vorangegangener 
Interventionen die Ergebnisse in den Studien beeinflussen oder beeinflusst 
haben. 
Die derzeit verfügbare Evidenz ist nicht ausreichend, um zu klären, ob die 
Meniskustransplantation zur Behandlung des Postmeniskektomie-Syndroms 
wirksamer als, und zumindest genauso sicher ist, wie ein konservativer The-
rapieansatz. 
 
Empfehlung  
Auf Basis der mangelnden Evidenz, die einen Vorteil der Meniskustransplan-
tation zur hauptsächlichen Vergleichsintervention – der konservativen The-
rapie – demonstriert und in der Ermangelung an adäquaten laufenden Stu-
dien, wird die Aufnahme in den Erstattungskatalog nicht empfohlen. 
 
 
2 laufende Studien, 
beides Fallserien 
derzeit keine 
Kostenerstattung 
sehr geringe 
Evidenzstärke 
fehlende 
Randomisierung  
in Studien,  
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kleine Studiengrößen 
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1 Scope 
1.1 PICO question 
In patients with post-meniscectomy syndrome, is meniscus allograft trans-
plantation more effective concerning changes in pain, changes in function, 
and necessity of total joint replacement, and as safe concerning complica-
tions and transplant failure in comparison to conservative management? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population  Patients with post-meniscectomy syndrome  
(i.e. pain, swelling and restricted movement after sub(total) meniscectomy). 
 Contraindications/exclusions: Significant articular cartilage wear. Significant articular 
cartilage wear is defined as Outerbridge Grade < III [1], or Ahlbäck Grade ≤ II [2]. 
 International classification of diseases (ICD)-10-CM code:  
M23.3 Other meniscus derangements 
 MeSH Terms: Tibial Meniscus Injuries [C26.558.781], Menisci,  
Tibial [A02.165.308.538, A10.165.382.350.163], Meniscectomy [E04.555.490] 
Rationale: International guidelines on the recommended use of meniscal allograft 
transplantation are not currently available. Therefore, the population has been defined 
based on the suggested indications in the reimbursement application, and informed by 
recent systematic reviews.[3-6] 
Intervention  Meniscal allograft transplantation (MAT) 
 Product names: Not applicable 
 MeSH Terms: Menisci, Tibial/transplantation*  
[A02.165.308.538.500, A02.835.583.475.590, A10.165.382.350.163.500] 
Control  Conservative management; including but not limited to physiotherapy, cortisone injections, 
pain management, bracing, activity modification, and weight loss. 
 No therapy/no treatment. 
Rationale: International guidelines on the recommended use of MAT are not currently 
available. The primary purpose of meniscal allograft transplant in the context of post-
meniscectomy syndrome is symptom control and to delay the need for total knee 
arthroplasty. In this context, alternative treatment options are limited. 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
Meniscal allograft transplantation for post-meniscectomy syndrome 
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Outcomes  
Efficacy Relevant clinical endpoints for efficacy include changes from pre- to post-treatment 
measurements of (critical outcomes are highlighted in bold): 
 Decrease in pain, including but not limited to: 
 Visual analogue scale (VAS) 
 International Knee Documentation Committee (IKDC) 
 Knee injury and Osteoarthritis Outcome Score (KOOS) 
 Increase in function, including but not limited to: 
 Lysholm Score 
 Tegner Score 
 KOOS 
 IKDC 
 Prolonged or prevented total joint replacement 
 Increase in quality of life (QoL), including but not limited to: 
 36-item Short Form Health Survey Questionnaire 
 KOOS-QoL 
 Return to daily activities 
Rationale: Appropriate clinical outcomes have been informed by systematic reviews [3, 6-9] 
and the EUnetHTA guidelines.[10] 
Safety Relevant safety outcomes include (critical outcomes are highlighted in bold): 
 Complications 
 Transplant failure/time to failure 
 Re-operation/additional surgery 
 Procedure-related mortality 
Rationale: Appropriate safety outcomes have been informed by a recent systematic  
review [3, 6] and the EUnetHTA guidelines.[11] 
Study design  
Efficacy  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 In the absence of comparative evidence, prospective case series will be included 
Excluded: narrative reviews, letter to the editor, author response, case reports. 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective case-series (n ≥ 40)  
Excluded: conference abstracts, narrative reviews, letter to the editor, author response,  
case reports, retrospective case series. 
Abbreviations: ICD = International classification of diseases; IKDC = International Knee Documentation Committee; 
KOOS = Knee injury and Osteoarthritis Outcome Score; MAT = meniscal allograft transplantation; QoL = Quality of life; 
VAS = Visual analogue scale. 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What are meniscal allograft transplantation (MAT) and conservative management? 
A0020 For which indications has meniscal allograft transplant received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of meniscal allograft transplant in relation to conservative management? 
B0003 What is the phase of development and implementation of meniscal allograft transplant  
and conservative management? 
B0004 Who administers meniscal allograft transplant and conservative management, and in what context 
and level of care are they provided? 
B0008 What kind of special premises are needed to use meniscal allograft transplant  
and conservative management? 
B0009 What supplies are needed to use meniscal allograft transplant and conservative management? 
A0021 What is the reimbursement status of meniscal allograft transplant? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is meniscal allograft transplant used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for post-meniscectomy syndrome? 
A0004 What is the natural course of post-meniscectomy syndrome? 
A0005 What is the burden of disease for patients with post-meniscectomy syndrome? 
A0006 What are the consequences of post-meniscectomy syndrome for society? 
A0024 How is post-meniscectomy syndrome currently diagnosed according to published guidelines  
and in practice? 
A0025 How is post-meniscectomy syndrome currently managed according to published guidelines  
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much are meniscal allograft transplant utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of meniscal allograft transplant on mortality? 
D0003 What is the effect of meniscal allograft transplant on the mortality due to causes other than  
post-meniscectomy syndrome? 
D0005 How does meniscal allograft transplant affect the symptoms and findings (severity, frequency)  
of post-meniscectomy syndrome? 
D0006 How does meniscal allograft transplant affect progression (or recurrence) of the disease  
or health condition? 
D0011 What is the effect of meniscal allograft transplant on patients’ body functions? 
D0016 How does the use of meniscal allograft transplant affect activities of daily living? 
D0012 What is the effect of meniscal allograft transplant on generic health-related quality of life? 
D0013 What is the effect of meniscal allograft transplant on disease-specific quality of life? 
D0017 Was the use of meniscal allograft transplant worthwhile? 
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Safety 
Element ID Research question 
C0008 How safe is meniscal allograft transplant in comparison to conservative management? 
C0002 Are the harms related to dosage or frequency of applying meniscal allograft transplant? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use of 
meniscal allograft transplant ? 
C0007 Are meniscal allograft transplant and conservative management associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of  
meniscal allograft transplant and conservative management? 
 
 
2.2 Sources 
A systematic literature search (see Section 2.3), supplemented by targeted 
hand searching, was used to identify relevant literature to answer the research 
questions. The specific sources that were used to inform the research ques-
tions on description of the technology, health problem and current use, in-
cluded: 
 Background publications identified in database search (see Section 2.3) 
and additional hand searching of specific databases (e.g. PubMed, 
Scopus) 
 Clinical practice guidelines identified by hand searching databases 
(e.g. www.guideline.gov) 
 Hand search of the CRD database for Health Technology Assessments 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the 22nd of December 2018 
in the following databases:  
 The Cochrane Library 
 Medline via Ovid 
 Embase  
 CRD (DARE, NHS-EED, HTA) 
The systematic search was limited to articles published in English or German. 
Before de-duplication, 1,009 citations were identified from the database search. 
The specific search strategy employed can be found in the Appendix.  
In addition, 8 relevant studies were identified through hand searching the re-
ference lists of included studies. Of these, only one relevant study was ulti-
mately identified; however this case series was not included due to sample 
size limitations (n<40).  
After de-duplication of the database searches and hand searches of reference 
lists, 721 hits were identified. In total, seven citations from six studies were 
included in the qualitative synthesis. 
systematische 
Literatursuche und 
gezielte Handsuche 
Quellen: 
Hintergrundliteratur aus 
systematischer Suche, 
Leitlinien mittels 
Handsuche 
systematische 
Literatursuche in 4 
Datenbanken  
systematische Suche: 
1.009 Zitate 
8 Treffer mittels 
Handsuche 
nach Deduplikation  
721 Treffer, davon  
6 Studien eingeschlossen 
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Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Trials) 
was conducted on the 3rd of January 2018. 
 
 
2.4 Flow chart of study selection 
The references were screened by two independent researchers and in case of 
disagreement a third researcher was involved to solve the differences. The 
selection process is displayed in Figure 2-1.  
 
a Two citations were included from the same study, with different follow-up results. 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2.5 Analysis 
Relevant data from the included studies were systematically extracted into 
data extraction tables by one reviewer (See Appendix Table A-1), based on 
study design and research question. The extracted data tables were validated 
for accuracy by a second reviewer. Relative risks were calculated from the pri-
mary data where necessary [using by: MedCalc©, Belgium, 20181]. No further 
processing of the data was conducted. (e.g., indirect comparison). 
Two independent researchers conducted quality appraisal, including risk of 
bias assessment, with differences settled via consensus. Quality appraisal was 
conducted with different tools presented in the Appendix, depending on study 
design (see Appendix Table A-2 and Table A-3). Risk of bias of non-random-
ised studies was evaluated using the ROBINS-I tool (formerly the ACRO-
BAT-NRSI tool) [12], as advised by the EUnetHTA Joint Action 2 reports on 
internal validity of randomised [13] and non-randomised studies [12]. Single 
arm case series were evaluated using the Institute of Health Economics check-
list [14]. 
 
 
2.6 Synthesis 
The research questions were answered in plain text format, with reference to 
GRADE (Grading of Recommendations Assessment, Development and Eval-
uation) included in Table A-4, the data-extraction in Table A-1, and the risk 
of bias tables in Table A-2 and Table A-3 [15]. No quantitative analysis of 
outcomes was performed, due limited number of relevant comparative trials 
identified. 
 
                                                             
1 MedCalc© (http://www.medcalc.org/calc/relative_risk.php) 
Datenextraktion und 
Kontrolle von  
2 Wissenschaftlern, 
relatives Risiko 
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Bewertung 
Studienqualität und 
Bias-Risiko durch  
2 Wissenschaftler, 
mittels Checkliste 
Evidenzsynthese  
mittels GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What are meniscal allograft transplantation (MAT) 
and conservative management? 
Meniscal allograft transplantation (technology) 
A meniscus is a wedge- or crescent-shaped piece of cartilage that sits in the 
knee, between the femur and tibia. There are two menisci in the knee; the 
lateral meniscus spans the lateral side of the knee joint, and the medial me-
niscus spans the medial side. The primary functions of the meniscus are to 
share the distribution of load forces in the knee, provide shock absorption, 
and lubricate the knee joint [16, 17].  
Irreparable meniscal tears are common in sporting and motor vehicle inju-
ries, or as a consequence of degenerative disease, and often require surgical 
treatment [18-20]. Meniscectomy procedures intended to remove some or all 
of a torn meniscus in an effort to improve pain and function [21]; however, 
this can result in increased contact stress between the femur and the tibia 
which can cause pain and instability. When a meniscectomy has failed, as de-
fined by ongoing pain in the affected knee compartment, a meniscal allograft 
transplant may be considered [19]. 
Meniscal allograft transplantation (MAT) is a procedure in which the menis-
cus from a cadaver is transplanted into a patient with a meniscal-deficient 
knee. The purpose of MAT is to restore a functional meniscus into the joint, 
with an aim to alleviate the symptoms associated with post-meniscectomy 
syndrome, and delay progression to osteoarthritis [18, 21].  
The transplantation is performed under general or spinal anaesthesia, and is 
conducted using either arthroscopy or mini-arthrotomy. The donor menisci 
are matched for size (right/left, lateral and medial) based on imaging studies 
of the recipients knee [6]. The graft is fixed in place using sutures, bone plugs 
or bridges depending on surgeon preference and fixation site [19]. Since me-
niscal tissue is no “living” tissue, immunosuppression is not needed.  
Other procedures to address underlying causes of joint degeneration or injury, 
such as anterior cruciate ligament (ACL) reconstruction are sometimes per-
formed at the same time as MAT [19].  
Following MAT, patients undergo personalised physiotherapy regimens to 
aid in the recovery process. Rehabilitation often includes weight bearing ex-
ercise, quadriceps strengthening, and restoring full range of motion [6]; how-
ever, there is currently no agreement in the literature around the most effec-
tive treatment regimens [6]. 
Conservative management (comparator) 
Conservative management for patients with post-meniscectomy knee pain is 
a multi-modal treatment approach, that is commonly specialised to the specif-
ic needs of the patient [22].  
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Physiotherapy is the core component of a conservative management approach, 
with an aim to increase the stability of the knee joint through strengthening 
the quadriceps, and increasing range of motion [23]. Over the longer term, 
exercises to improve strength, flexibility and proprioception may be indicat-
ed [21].  
Oral pain medication and non-steroidal anti-inflammatory drugs are common-
ly used to manage mild pain and inflammation in the knee [24]. Similarly, 
cortisone or analgesic knee injections are often used in order to confirm a di-
agnosis of post-meniscectomy syndrome, and to provide symptomatic relief 
for stronger pain [22, 24].  
Behaviour modification may be advised in order to reduce stresses that can 
exacerbate knee pain, and to encourage weight loss [22].  
No treatment 
The final alternative to MAT is to offer no treatment, and instead watch and 
wait for symptoms to progress (or not). 
Alternative meniscus transplants 
Alternatives to MAT, such as synthetic meniscus transplants and scaffolds, 
have been developed in order to combat the limited supply of donor allografts 
[19]. These products are considered to be experimental and are therefore not 
considered in this review [25]. 
A0020 – For which indications has meniscal allograft transplantation 
received marketing authorisation or CE marking? 
Human meniscal allografts are not classified as medical devices, and therefore 
are not subject to CE marking.  
Human tissue donation is regulated in the European Union under the Euro-
pean Union Tissue and Cells Directives (EUTCD) 2004/23/EC. The EUTCD 
outlines the legal framework for the supply of tissues and cells within the EU, 
to ensure that biological samples meet acceptable safety and quality stand-
ards [26]. In this regard, individual suppliers of tissue samples that are li-
censed to distribute tissue samples under the EUTCD are able to distribute 
meniscal allografts within the EU. 
Moreover, the principles of tissue and organ donation in Austria is positioned 
in the „Bundesgesetz über die Transplantation von menschlichen Organen“ 
(Organtransplantationsgesetz – OTPG) [27].  
B0002 – What is the claimed benefit of meniscal allograft 
transplantation in relation to conservative management? 
Meniscal allograft transplantation aims to restore the meniscal function in pa-
tients with previously removed menisci. In the context of post-meniscectomy 
syndrome, published literature on MAT suggests the primary aims of treat-
ment are to relieve pain and effusions, restore functional capacity, lower the 
risk of osteoarthritis progression, and delay the requirement for total or par-
tial knee arthroplasty and associated revision procedures [22, 28, 29]. In this 
regard, MAT is proposed to have superior effectiveness compared to conserva-
tive management [20]. 
As MAT is an additional surgical procedure, complications associated with 
MAT are considered to be additional safety risks not otherwise borne by pa-
tients treated with conservative management.  
Physiotherapie ist 
Hauptbestandteil 
zusätzlich Medikamente 
und gegebenenfalls 
Injektionen 
eventuell auch 
Verhaltensanpassung 
keine Therapy auch 
Alternative 
andere Alternativen, wie 
synthetische Menisken 
derzeit experimentell 
keine Medizinprodukte, 
daher kein CE 
Gewebe- und 
Organspenden in EU 
über EUTCD geregelt 
gesetzliche Verankerung 
in Österreich über 
Bundesgesetz 
Meniskustransplantation 
zielt darauf ab 
Schmerzen zu reduzieren 
und langfristig eine 
Gelenksarthrose zu 
vermeiden 
Transplantation birgt 
zusätzliche Risiken,  
da Operation 
Description and technical characteristics of technology 
LBI-HTA | 2018 19 
The submitting hospital did not propose a specific clinical claim in relation 
to an appropriate comparator, rather that there is no alternative technique for 
meniscal replacement in the context of post-meniscectomy syndrome.  
B0003 – What is the phase of development and implementation of 
meniscal allograft transplantation and conservative management? 
Meniscal allograft transplantation was initially reported in 1984 and it has 
since been the subject of numerous publications [30, 31]. Although MAT is 
not a new orthopaedic procedure, it is not widely performed in most hospitals 
[32]. This is also reflected in the paucity of clinical practice guidelines rec-
ommending the use of MAT for treating post-meniscectomy syndrome. 
Due to the lack of treatment options for post-meniscectomy syndrome, pa-
tients are currently treated by conservative management. This is largely be-
cause physiotherapy is a widely available treatment for knee injuries and re-
habilitation, and does not carry the surgical risks associated with MAT [23]. 
However, there is not one accepted definition or treatment regime that con-
stitutes conservative management for post-meniscectomy syndrome. Rather, 
treatment aims are typically designed to meet the requirements of a specific 
patient [22].  
 
Administration, Investments, personnel and tools required  
to use the technology and the comparator(s) 
B0004 – Who administers meniscal allograft transplantation  
and conservative management, and in what context and level of care  
are they provided? 
B0008 – What kind of special premises are needed to use meniscal 
allograft transplantation and conservative management? 
Meniscal allograft transplantation should be performed by an orthopaedic sur-
geon that is fellowship trained in arthroscopic surgery of the knee. The pro-
cedure can be performed with the patient under a general anaesthetic or with 
a spinal block, depending on the patient’s preference and associated risks [33]. 
The procedure should be done in a medical centre that is accustomed to do-
ing arthroscopic meniscectomies [33].  
Meniscal transplant surgery can be performed with either an open or arthro-
scopic approach. If performed arthroscopically, MAT can be performed in 
either an outpatient or inpatient setting [28, 33]. For both approaches, sterile 
operating theatres are required. 
Conservative management can be provided by trained physiotherapists or 
occupational therapists. They can be administered in all facilities, whereas 
specific weight bearing exercises may require gym equipment. 
B0009 – What supplies are needed to use  
meniscal allograft transplantation and conservative management? 
The supplies required are dependent on the type of graft used (i.e. fresh-fro-
zen, cryopreserved, deep frozen, fresh or freeze-dried), how the graft is sized, 
and the surgical approach (open or arthroscopic technique) [28, 34].  
Frozen grafts and cryopreserved grafts require refrigeration for storage. Fresh 
allografts require lactated ringer’s solution at 4°C. Saline solution is required 
for thawing grafts [34]. 
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Sizing of allografts can be done using radiography, computed tomography, 
magnetic resonance imaging (MRI) or with direct measurements [28, 34]. 
General surgical equipment includes anaesthesia, prophylactic antibiotics, a 
tourniquet and compression devices, arthroscopic equipment, sutures to at-
tach the graft and guide pins [3, 34]. 
The bone plug technique requires additional equipment including; bone plugs, 
oscillating saw, coring reamer, ronguer, specific needles and sutures, menis-
cal repair joystick instrument set system, knife, retriever/grasper and Swive-
Lock Anchor [35]. 
Conservative management may require knee braces (those are also needed for 
post-surgical treatment), injections, and potentially weight or resistance equip-
ment for strength training. Injections may require local anaesthesia to ad-
minister [24]. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of meniscal allograft 
transplantation? 
Meniscal allograft transplantation is not currently included in the Austrian 
hospital benefit catalogue, and therefore is not reimbursed by the Austrian 
health care system. However, the intervention could be billed under another 
code, like for arthroscopic operations of the knee joint (Code NF020 – Ar-
throskopische Operationen des Kniegelenks) or refixations of the meniscus 
(NF040 – Meniskusrefixation – arthroskopisch). 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and  
for what purposes is meniscus allograft transplantation used? 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
The health condition under investigation for this assessment is post-menis-
cectomy syndrome, characterised by intractable pain in the knee due to prior 
subtotal or total meniscectomy. 
Meniscectomy has been performed for the management of meniscal tears for 
many years; however, following surgery some patients develop unicompart-
mental knee pain without significant articular cartilage wear, known as ‘post-
meniscectomy syndrome’ [22]. The purpose of MAT is to substitute the miss-
ing meniscus, thereby restoring the load-bearing, shock absorption and lu-
brication mechanisms in the knee and reduce pain [16, 17]. 
A0003 – What are the known risk factors  
for post-meniscectomy syndrome? 
The pathogenesis of post-meniscectomy syndrome is not clear [22]. Removal 
of the meniscus, whilst effective in relieving symptoms for some patients, has 
long term consequences for the knee joint. Further, meniscectomy a risk fac-
tor for pain and functional impairment over the longer term (thus, the gen-
eral aim is to preserve the meniscus, if possible) [36, 37]. Factors that might 
increase the risk of post-meniscectomy syndrome include: degenerative chang-
es in the knee joint contributing to pain, lateral meniscectomy (as compared 
to medial meniscectomy), poor vascular supply to the repair zone, underlying 
malalignment of the knee, and factors contributing to greater joint loading 
such as high activity level and/or body mass index [22, 38].  
A0004 – What is the natural course of post-meniscectomy syndrome? 
Meniscectomy increases the risk of osteoarthritis [36, 37]; however, this ele-
vated risk does not guarantee a patient who has had a subtotal or total me-
niscectomy will progress to osteoarthritis [39]. 
Osteoarthritis leads to cartilage damage. The extent of cartilage damage can 
be classified using the following grading systems (see Tables 4-1 to 4-3): 
Table 4-1: Classification of cartilage defects by Outerbridge  
Grade Characteristics 
0 Normal 
1 Softening and swelling of cartilage 
2 Fragmentation and fissuring, less than 1.5 cm-in diameter 
3 Fragmentation and fissuring, greater than 1.5 cm in diameter 
4 Erosion of cartilage down to exposed subchondral bone 
Reference: [1] 
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Table 4-2: Classification of osteoarthritis of the knee joint by Ahlbäck  
Grade Characteristics 
1 Joint space narrowing (les than 3mm) 
2 Joing space obliteration 
3 Minor bone attrition (0-5mm) 
4 Moderate bone attrition (5-10mm) 
5 Severe bone joint attrition (more than 10mm) 
Reference: [2] 
Table 4-3: Classification of chondral defects by International Cartilage Repair Society  
Grade Characteristics 
0 Normal 
1 Nearly normal  
(soft indentation and/or superficial fissures and cracks) 
2 Abnormal (lesions extending down to <50% of cartilage depth 
3 Severely abnormal (carilage defects >50% of cartilage depth 
4 Severely abnormal (through the subchondral bone) 
Reference: [40] 
 
Progression to osteonecrosis is another potential risk factor of post menis-
cectomy; however, the natural progression is not well understood [41]. There 
are a number of proposed mechanisms that can lead to osteonecrosis of fem-
oral condyles, including: 
 Overloading, causing impaired circulation in subchondral bone; 
 Subchondral insufficiency fracture due to abnormal load transfer; and 
 Intraosseous contact. 
In addition to osteoarthritis, meniscectomy also increases the risk of total 
knee replacement [42]. 
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden   
of diseasefor patients with post-meniscectomy syndrome? 
Patients with post-meniscectomy syndrome are suffering from pain and im-
paired mobility [43], leading to a lower quality of life. 
In addition, the syndrome can lead to the development of degenerative oste-
oarthritis and a further progression can lead to the requirement of a joint re-
placement [42, 44, 45]. 
A0006 – What are the consequences  
of post-meniscectomy syndrome for society? 
In 2016 there were nearly 80,000 surgeries of the knee joint in Austria. Of 
these, a total of 38,771 interventions were arthroscopic surgeries [46, 47]. How-
ever, no information on the number of meniscectomies, and the consequent 
risk of post-meniscectomy syndrome, has been identified. 
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The long-term consequences of post-meniscectomy syndrome can lead to high 
costs for required treatments, such as physiotherapy, medication, and surger-
ies (including total joint arthroplasty). Total knee arthroplasty is reimbursed 
for approximately 9,000 Euros [48-50]. In addition, there are indirect costs 
associated with post-meniscectomy syndrome, such as time and productivity 
losses, especially when considering that mainly young people in the age be-
tween 20 and 50 years are affected. However, an estimation of the interven-
tional or total costs of post-meniscectomy syndrome for the society is not pos-
sible. 
 
Current clinical management of the disease or health condition 
A0024 – How is post-meniscectomy syndrome currently diagnosed 
according to published guidelines and in practice? 
We could not identify published guidelines on the diagnosis of post-menis-
cectomy syndrome. Studies included in this report noted that the syndrome 
is confirmed by the presence of symptoms in the context of prior meniscec-
tomy. Symptoms experienced by patients following meniscectomy included 
ipsilateral joint-line pain, activity-related swelling, crepitus, post activity ef-
fusions and the occasional giving way of the knee [51-53]. Patients are as-
sessed for their suitability for MAT by a combination of MRI, x-rays, and ar-
throscopic images [53-55]. 
A0025 – How is post-meniscectomy syndrome currently managed 
according to published guidelines and in practice? 
No evidence-based guidelines for the treatment of post-meniscectomy syn-
drome were identified in this review. In practice, the main treatment options 
include no treatment, conservative management or surgery. 
Generally, the treatment of post-meniscectomy aims at pain reduction, regain-
ing joint mobility, prevention of osteoarthritis, and eventually avoiding total 
joint replacement. No treatment, however, will probably not improve symp-
toms, but it can be considered as comparator (see section 1.1). 
Conservative management is described in section “B0001 – What are menis-
cal allograft transplantation (MAT) and conservative management?”. 
A last resort to treat post-meniscectomy pain is total knee arthroplasty (TKA). 
This procedure involves the removal of the damaged cartilage and bone from 
the knee joint and replacing it with a man-made joint of metal and plastic or 
ceramic. The surgery can cause scarring, blood clots, and, rarely, infections. 
Due to the high invasiveness of TKA, it is considered as a last resort treat 
post-meniscectomy pain, and is therefore not considered to be an appropri-
ate comparator to MAT. 
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Target population 
A0007 – What is the target population in this assessment? 
The primary indications for MAT have not been clearly established in the lit-
erature. Recent technical and systematic reviews recommend specific criteria, 
including [4, 28, 33]:  
1. Patient age between 20 and 50 years 
2. Previous meniscectomy 
3. No severe degenerative changes to articular cartilage 
4. Joint stability 
5. Local pain and swelling in the meniscus-deficient compartment 
6. Normal lower limb alignment 
Due to the clinical uncertainty around the proposed population, the target 
population in this assessment is broadly defined as patients with post-me-
niscectomy syndrome, and no significant articular cartilage wear. Significant 
articular cartilage wear is defined as Outerbridge Grade < III [1], or Ahlbäck 
Grade ≤ II [2]. 
A0023 – How many people belong to the target population?  
No information on the Austrian, European or international data for the prev-
alence or incidence of post-meniscectomy syndrome was identified to inform 
this research question. Similarly, the frequency of meniscectomies conducted 
in Austria is currently unknown. 
A0011 – How much is meniscus allograft transplantation utilised? 
There is currently no data that can be used to estimate the overall size of the 
population that is eligible for MAT. 
Based on the information provided in the VAEV, the estimated annual utili-
sation of MAT in the submitting hospital is around 10 procedures. In con-
trast, the annual utilisation in Austria is estimated to be around 200 proce-
dures.  
It is not possible to estimate the number of patients with post-meniscectomy 
syndrome that are currently treated with conservative management. 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as critical to derive a recommendation: 
 Decrease in pain 
 Increase in function 
 Prolonged or prevented total joint replacement 
The clinical outcomes chosen as critical to derive a recommendation are based 
on the primary treatment goals of MAT (see “A0025 – How is post-meniscec-
tomy syndrome currently managed according to published guidelines and in 
practice?”).  
Pain is the primary symptom that is used to diagnose post-meniscectomy syn-
drome. It is most often measured using patient-reported or observer-report-
ed questionnaire scales, and as such is difficult to measure objectively. Pain 
can be measured using generic scales, such as a visual analogue scale, or dis-
ease-specific questionnaires, such as the Knee injury and Osteoarthritis Out-
come Score (KOOS) pain subscale for knee osteoarthritis. 
Function is a measure of how the disease impacts daily life and activities. It 
can be measured using a range of different scoring tools, including:  
 KOOS is a composite measure of a patient’s opinion about their knee, 
incorporating 5 subscales: pain (KOOS-Pain), other symptoms, func-
tion in daily life (KOOS-ADLs), function in sports and recreation 
(KOOS-Sports), and knee-related quality of life (KOOS-QoL). The 
KOOS and subscale scores range from 0 (extreme symptoms/disabil-
ity) to 100 (no symptoms/disability) [56]. 
 The Lysholm scale is a composite measure of knee function, adminis-
tered by clinicians, ranging between 0 (severe symptoms/disability) 
and 100 (no symptoms/disability) [56]. 
 International Knee Documentation Committee (IKDC) is a subjective, 
patient-reported knee evaluation form designed to detect changes in 
symptoms, function and sports activities due to knee impairment. The 
IKDC is a composite measure of overall function ranging from 0 (se-
vere symptoms/disability) to 100 (no symptoms/disability) [56]. 
Prolonging or preventing total joint replacement is a key long-term treat-
ment goal of MAT. This outcome is measured by reported rates of TKA fol-
lowing MAT or conservative management (or no treatment). In order to eval-
uate this outcome comprehensively, long-term follow-up data is required. 
In addition to the critical outcomes, two additional outcomes were considered 
to be important but not critical to the decision: 
 Increase in quality of life 
 Return to daily activities 
Quality of life and return to daily activities are important outcomes of MAT, 
which follow as a consequence of achieving the primary treatment goals. These 
two outcomes were considered to be important, though not crucial, because 
pain and function affect quality of life and the return of patients to daily ac-
tivities. 
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5.2 Included studies 
To evaluate the effectiveness of MAT for treating post-meniscectomy syn-
drome, we considered RCTs and non-randomised studies comparing MAT to 
conservative management or no therapy/treatment.  
Only one comparative study met the pre-defined inclusion criteria; a prospec-
tive cohort study with a nested RCT, which compared MAT with conservative 
management [23]. This study was categorised as a cohort study despite includ-
ing a nested RCT, because the results of the randomised and non-randomised 
groups were combined. Therefore, this study is considered to be a cohort study 
for the purposes of this review. 
The cohort study was conducted in the United Kingdom and enrolled 36 pa-
tients with post-meniscectomy syndrome, where the treating surgeon thought 
the patient would benefit from MAT [23]. 
From the total sample, 21 patients were randomised to receive either MAT or 
physical knee therapy, and the remaining 15 patients were allowed to select 
their treatment allocation. This design was used in order to maximise recruit-
ment numbers. All patients received physiotherapy rehabilitation following 
MAT. 
The average age of participants was 29 in the MAT group and 27 in the con-
servative management group, and the average time since meniscectomy to 
treatment was similar between groups (8.2 years vs 7.6 years). The majority of 
the sample were male (n=26, 72%). There was a greater proportion of lateral 
compared to medical menisci treated overall (n=28 vs 8), and a slightly high-
er proportion of lateral menisci were treated in the MAT group (87.5% vs 
70.0%) [23]. 
The study did not specify the clinical grade of cartilage status, but reported-
ly excluded patients that had exposed subchondral bone due to arthritis, and 
those who had undergone previous cartilage modifying procedures. Three 
MAT patients had concomitant osteotomy [23]. The number of previous sur-
geries was not reported. 
Study characteristics and results of the included study are displayed in Ta-
ble A-1, Table A-2, and in the evidence profile in Table A-6. 
Since we could not identify any controlled studies comparing MAT with no 
therapy/no treatment, the results are exclusively for MAT versus conserva-
tive treatment. 
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5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect  
of meniscal allograft transplant on mortality? 
D0003 – What is the effect of meniscal allograft transplant  
on the mortality due to causes other than post-meniscectomy syndrome? 
Since post-meniscectomy syndrome is not life-threatening, and MAT was con-
sidered not to have an effect on mortality, these research questions are not 
relevant. However, procedure-related mortality was considered as safety-out-
come (see “C0008 – How safe is meniscal allograft transplant in comparison 
to conservative management?”) 
 
Morbidity 
D0005 – How does meniscal allograft transplant affect the symptoms 
and findings (severity, frequency) of post-meniscectomy syndrome? 
Answering this research question was based on the critical outcome “pain”. 
Patient-reported pain was measured using the KOOS-Pain subscale question-
naire [23]. Pain scores were measured at baseline and after 12 months. The 
mean change in pain score at 12 months was compared between the MAT and 
physiotherapy groups.  
After 12 months, the mean difference in the change in KOOS-Pain score from 
baseline was 15.1 (95% CI 2.4 to 27.8, p=0.021) (Figure 6-1). These results 
demonstrate a significantly greater improvement in knee-related pain in fa-
vour of MAT [23]. 
 
Figure 6-1: Mean change in Knee injury and Osteoarthritis Outcome Score (KOOS).  
Subscales from baseline to 12 months in the pooled meniscal allograft 
transplantation (MAT) and personalized knee therapy (PKT) group.  
QoL = Quality of life; ADL = activities of daily living  
(Reference: Smith 2018 [23]). 
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Furthermore, the identified study also reported on symptoms (see Figure 6-1) 
by using the KOOS-Symptoms subscale; a composite score comprised of swell-
ing, noise (e.g. clicking), knee locking, straightening and bending [56]. How-
ever, since we did not consider this outcome in our PICO question (pain and 
function scores were considered to be the most relevant outcomes to express 
symptoms), this outcome was not extracted. Nevertheless, the improvement 
in symptoms was not significantly higher for MAT-patients compared to 
physiotherapy (mean difference 5.7, 95% CI -6.4 to 17.9, p=0.341) [23]. 
D0006 – How does meniscal allograft transplant affect progression 
(or recurrence) of post-meniscectomy syndrome? 
This research question was supposed to be answered by the critical outcome 
“necessity of total joint replacement”. However, no comparative data were 
identified on this outcome. Thus, this research question cannot be answered. 
 
Function 
D0011 – What is the effect of meniscal allograft transplant on patients’ 
body functions? 
This research question is answered within the following section (“D0016”). 
D0016 – How does the use of meniscal allograft transplant affect 
activities of daily living? 
Function scores were the primary outcomes used to determine the impact of 
MAT in comparison to conservative management on activities of daily living. 
Function was measured using the KOOS-ADL, KOOS-Sports and KOOS-
Composite subscale questionnaires, as well as Lysholm and IKDC question-
naires [23]. Function scores were measured at baseline and after 12 months. 
The mean change in function scores at 12 months were compared between the 
MAT and physiotherapy groups.  
The mean difference in the change in scores was not statistically significant 
for Lysholm (MD=7.3, 95% CI -4.5 to 19.1, p=0.22), IKDC (MD=8.4, 95% 
CI -3.6 to 20.5, p=0.16) or KOOS-Sports (MD=14.0, 95% CI -2.7 to 30.8, 
p=0.098, see also Figure 6-1) [23]. 
Significant increases in function scores, favouring MAT, were observed for 
KOOS-Composite (MD 11.9, 95% CI 1.1 to 22.7, p=0.034), and KOOS-ADL 
(MD 18.2, 95% CI 6.0 to 30.5, p=0.005, see also Figure 6-1) [23]. 
 
Health-related quality of life 
D0012 – What is the effect of meniscal allograft transplant  
on generic health-related quality of life? 
No comparative data on generic health-related quality of life was identified 
to answer this question. 
  
weiterer Endpunkt: 
KOOS-Symptome  
keine signifikanten 
Unterschiede zwischen 
Studiengruppen 
Frage kann nicht 
beantwortet werden,  
da keine Evidenz 
Frage mit nachfolgender 
Frage zusammengelegt 
Scores zu  
Funktionalität 
Messung in Studie 
mittels verschiedener 
Scores 
keine signifikanten 
Unterschiede bei 
Lysholm, IKDC und 
KOOS-Sports 
Transplantation 
signifikant besser bei: 
KOOS-Composite und 
KOOS-ADL 
keine Evidenz 
Clinical effectiveness 
LBI-HTA | 2018 29 
D0013 – What is the effect of meniscal allograft transplant  
on disease-specific quality of life? 
Disease-specific quality of life was measured using the KOOS-QoL subscale 
questionnaire [23]. Quality of life scores were measured at baseline and after 
12 months. The mean change in KOOS-QoL scores at 12 months was com-
pared between the MAT and physiotherapy groups.  
After 12 months, the mean difference in the change in KOOS-QoL score from 
baseline was 12.6 (95% CI -0.4 to 25.6, p=0.058, see also Figure 6-1) favour-
ing MAT [23]. These results demonstrate a minimum clinically important 
increase in knee-related quality of life in favour of MAT [57], but which did 
not reach statistical significance. 
 
Patient satisfaction 
D0017 – Was the use of meniscal allograft transplant worthwhile? 
No comparative data was identified to answer this question.  
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as critical to derive a recommendation: 
 Complications 
 Transplant failure/time to failure 
Procedure-related complications are adverse events that are specifically re-
lated to the intervention [24]. Complications have been defined broadly as to 
be inclusive of all types of adverse events that may be related to MAT or con-
servative management. Possible procedure-related complications of MAT in-
clude, but are not limited to, infection, meniscal tears, haematoma, and ar-
throfibrosis. 
Transplant failure can be measured in a number of ways, including persis-
tent pain after MAT, removal of the graft, or progression to the requirement 
for TKA [51, 52, 54, 58]. Graft failures often require invasive additional sur-
geries and, depending on their timing, may also demonstrate clinically inap-
propriate care. 
In addition to the critical outcomes, two additional outcomes were considered 
to be important but not crucial to the decision: 
 Re-operation/additional surgery 
 Procedure-related mortality 
Re-operations are an indication of additional procedures that were directly 
caused by implementation of the intervention or comparator. Re-operations 
can result in additional time, resources, and risks. They were included as im-
portant outcomes, but not critical, as all major complications that required 
re-operation are likely to be captured under the complications and transplant 
failure outcomes. 
Procedure-related mortality is a very rare but potential outcome of MAT. 
This outcome has been included in order to determine whether or not there 
is any procedure-related mortality risk associated with MAT. 
 
 
6.2 Included Studies 
Study characteristics and results of the included studies are displayed in Table 
A-1 and in the evidence profile in Table A-6. 
A total of six studies with a total of 344 patients were identified to inform the 
recommendation on the safety of MAT. Five case series [51-55, 58] and one 
cohort study with a nested RCT, comparing MAT with conservative treatment 
[23] were included. All were prospective in design. Follow-up time ranged 
between 12 to 120 months. The case series reported all results at a mean fol-
low-up time (range 22 to 56 months) [51-55, 58], whereas the cohort study 
reported all results at 12-month follow-up [23]. 
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Patient numbers ranged from 40 to 88 in the case series [51-55, 58]. In the 
cohort study with nested RCT, 21 patients were included in the RCT and 15 
in the non-randomised group [23]. Mean patient age ranged from 25 to 40 
years across all studies. 
With respect to the intervention, two studies used MAT with bone plug fixa-
tion [52, 53], two studies used MAT with soft tissue fixation [23, 54, 55], one 
study used MAT with suture-only or bony fixation [51]. The remaining study 
used MAT with bone block and/or soft tissue fixation for lateral menisci, and 
soft tissue fixation alone for medial menisci [58]. 
Three of the included studies reported that patients had undergone prior sur-
geries [51-53]. Prior surgery status was not reported in the other three stud-
ies. All studies reported that at least some of the patients had concomitant 
interventions with the number ranging from 18% to 50% [23, 51-55, 58]. The 
types of concomitant interventions included osteotomies, ACL reconstruc-
tions, microfracture, chondral shaving, hardware removal, autologous chon-
drocyte implantation, ligament reconstructions, osteoarticular allografts and 
osteochondritis dissecan fixations. 
In the case series studies, patients were reported as low-grade cartilage dam-
age, indicated by Outerbridge Grade 0-II [52, 53], Ahlbäck Grade I, Interna-
tional Cartilage Repair Society (ICRS) Grade 0-3b involving <1cm2 (defined 
as ‘good’ in the study) [54, 55]. One case series did not describe cartilage sta-
tus [58], and as such the applicability of the population in this study is un-
certain. 
Since we could not identify any controlled studies comparing MAT with no 
therapy/no treatment, the comparative results are exclusively for MAT ver-
sus conservative treatment. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is meniscal allograft transplant in comparison 
to conservative management? 
To answer this research question, the outcomes “complications”, “transplant 
failure”, “time to failure”, and “transplant failure” were considered. 
MAT vs. conservative management 
The relative risk of complications for MAT was 6.92 (95% CI 0.91 to 52.45, 
p>0.05) compared to conservative management; however, this difference was 
not statistically significant. Further, the complications in the MAT group were 
not adequately defined [23]. 
All five complications in the MAT group required re-operation with arthros-
copy, whereas the only complication in the conservative management group 
was a thigh bruise that did not require any intervention [23]. 
Transplant failure and time to failure were not reported. 
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Single arm studies 
The overall complication rate for MAT across all of the case series was 20.2% 
(range 0.0% to 30%). All but one complication (56 of 57) related to MAT re-
quired re-operation, typically with an arthroscopic procedure [51, 52, 54, 55, 
58]. Specific complications reported in the single-arm trials are described in 
Table A-1. 
The overall failure rate of meniscal allografts was 4.4% (range 1.7% to 7.7%) 
at a mean follow-up time of 46 months (range 13 to 120) [51, 52, 54, 55, 58]. 
Time to failure was only reported by one study, which reported three failures 
(7.7%) with a mean time to failure of 15 months (range 9 to 21 months) [52]. 
No instances of procedure-related mortality were reported in any of the in-
cluded studies (0.0%, 0/295) [23, 51-55, 58]. 
C0002 – Are the harms related to dosage or frequency  
of applying meniscal allograft transplant? 
No reliable data was identified to answer this research question. It is unclear 
if patients are likely to be considered for a replacement of MAT on a previ-
ously treated transplanted compartment.  
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No reliable data was identified to answer this research question. The con-
trolled cohort study reported results for all outcomes at 12-month follow-up 
[23]. The case series reported complication and failure rates at an overall mean 
follow-up time, which varied between studies (range 30 to 60 months) [51-
55,58] (see also question “C0008 – How safe is meniscal allograft transplant 
in comparison to conservative management?”). Relative survival rates of MAT 
in patients with varying levels of cartilage degeneration are reported below 
(see question “C0005” below). 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of meniscal allograft transplant? 
MAT cartilage Grade: ‘Good’ vs ‘Bare’ 
One study investigated graft survival rates of meniscal allografts in patients 
with ‘good’ (n=60) versus ‘bare’ cartilage status (n=39). ‘Good’ cartilage was 
defined as ICRS Grade 3b chondral damage of <1cm2, while ‘bare’ was de-
fined as ICRS Grade 3b chondral damage of >1cm2 or worse [54]. 
Patients with ‘good’ cartilage status reported significantly greater 2-year sur-
vival compared to patients with ‘bare’ cartilage (97.9% vs 78.0%, p=0.002) 
[54]. Similarly, the ‘good’ cartilage group reported significantly lower overall 
complication rates (30% vs 46%, p=0.05), and significantly lower major com-
plication rates (13% vs 31%, p=0.035) [54]. 
MAT fixation type: Suture vs Bone Plug 
One study reported the relative complication rate of MAT using suture fixa-
tion compared to bone plug fixation. Suture fixation reported a 33.3% (n= 
11/33) complication rate, including seven re-operations for graft tears. Of 
these, three grafts had to be removed completely (i.e. transplant failure) [51]. 
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In comparison, the bone-plug technique reported a 16.4% (n=9/55) compli-
cation rate, including four tears that results in re-operations. In two of these 
operations the graft had to be removed completely (i.e. transplant failure) [51].  
Neither the reported difference in complications nor graft failures were sta-
tistically significant [51]. 
C0007 – Are meniscal allograft transplant and  
conservative management associated with user-dependent harms? 
No evidence was identified to answer this question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed to monitor 
the use of meniscal allograft transplant and conservative management? 
No evidence was found to answer this research question. International, pro-
spective registry data will better inform the long-term safety of MAT; how-
ever, due to the absence of clinical data on the comparative effectiveness of 
MAT, this type of resource-intensive monitoring strategy is not warranted at 
present. 
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7 Quality of evidence 
Risk of bias in the cohort study was appraised using the ROBINS-I tool [59], 
and is presented in Table A-2 (see Appendix). Importantly, this study was 
categorised as a cohort study despite including a nested RCT, because the 
results of the randomised and non-randomised groups were combined. The 
comparative study had a serious overall risk of bias due to possible con-
founding, selection bias, missing data, and the use of un-blinded patient-
reported outcome measures.  
Risk of bias in the single arm studies was appraised using the Institute of 
Health Economics (IHE) appraisal tool for case series studies [14], and is 
presented in Table A-3 (see Appendix). The single arm studies were at mod-
erate to serious risk of bias. The main reasons for increasing the risk of bias 
were due to single-centre design, unclear method for capturing complica-
tions, poor reporting of the follow-up period, and failure to disclose both 
competing interest and sources of support for the study. 
The strength of evidence was rated according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) Schema [60] for 
each endpoint individually. Each study was rated by two independent re-
searchers. In case of disagreement a third researcher was involved to solve 
the difference. A more detailed list of criteria applied can be found in the 
recommendations of the GRADE Working Group [60].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below (Table 7-1) and in the evi-
dence profile in Appendix Table A-6. 
Overall, the strength of evidence for the effectiveness and safety of MAT in 
comparison to conservative management is “very low”. The strength of evi-
dence for the safety of MAT from the identified case series is also “very low”. 
Moreover, we could not identify any comparative studies on MAT versus no 
therapy/no treatment. 
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Table 7-1: Summary of findings table of meniscal allograft transplantation (compared to conservative management) for the treatment of post-meniscectomy syndrome 
Outcome 
Anticipated absolute effects (95% CI) 
Relative effect 
(95% CI) 
Number of 
participants 
(studies) 
Quality Comments 
Risk with MAT 
Risk with 
conservative 
management Difference 
EFFICACY 
Pain: Change in pain score  
Follow up: 12 months; assessed with: 
KOOS – Pain Subscale; Scale from: 0 to 100  
NR NR MD 15.1 points higher 
in MAT group 
(2.4 higher to 
 27.8 higher) 
Not estimable 31 
(1) 
⨁◯◯◯ 
VERY LOW2,3 
Higher scores indicate 
improved pain 
Function: Change in function score  
Follow up: 12 months; assessed with: 
Lysholm; Scale from: 0 to 100  
NR NR MD 7.3 points higher 
in MAT group 
(4.5 lower to  
19.1 higher) 
Not estimable 31 
(1) 
⨁◯◯◯ 
VERY LOW2,3 
Higher scores indicate 
improved function, no 
significant differences 
Function: Change in function score 
Follow up: 12 months; assessed with: 
IKDC; Scale from: 0 to 100 
NR NR MD 8.44 points 
higher in MAT group 
(3.8 lower to  
20.5 higher) 
Not estimable 31 
(1) 
⨁◯◯◯ 
VERY LOW2,3 
Higher scores indicate 
improved function, no 
significant differences 
Function: Change in function score  
Follow up: 12; assessed with: KOOS-
Composite; Scale from: 0 to 100 
NR NR MD 11.9 points higher 
in MAT group 
(1.1 higher to  
22.7 higher) 
Not estimable 31 
(1) 
⨁◯◯◯ 
VERY LOW2,3 
Higher scores indicate 
improved function 
Function: Change in function score  
Follow up: 12; assessed with: KOOS-ADL; 
Scale from: 0 to 100 
NR NR MD 18.2 points higher 
in MAT group 
(6 higher to  
30.5 higher) 
Not estimable 31 
(1) 
⨁◯◯◯ 
VERY LOW2,3 
Higher scores indicate 
improved function 
Function: Change in function score 
Follow up: 12; assessed with: KOOS-Sports; 
Scale from: 0 to 100 
NR NR MD 14 points higher 
in MAT group 
(2.7 lower to  
30.8 higher) 
Not estimable 31 
(1) 
⨁◯◯◯ 
VERY LOW2,3 
Higher scores indicate 
improved function, no 
significant differences 
Necessity of total joint replacement - - - - - - Outcome not reported 
                                                             
2 There was a serious risk of bias due to possible confounding, missing data, the use of unblinded patient-reported outcome measures and inadequate reporting of complications 
3 Sample size is below optimal information size. Conventional sample size calculation required 50 patients in each study arm. 
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Outcome 
Anticipated absolute effects (95% CI) 
Relative effect 
(95% CI) 
Number of 
participants 
(studies) 
Quality Comments 
Risk with MAT 
Risk with 
conservative 
management Difference 
SAFETY 
Complications (comparative) 
Follow up: 12 months 
384 per 1,000 
(51 to 1,000) 
56 per 1,000 32.9% more  
(0.5 fewer to  
285.8 more) 
RR 6.92 
(0.91 to 52.45) 
31 
(1) 
⨁◯◯◯ 
VERY LOW4,5,6 
All complications in the 
MAT group required re-
operation, no significant 
differences 
Complications (single arm) 
Follow up: range 13 months to 120 months 
Overall complications: 57/282 
(20.2%, range 0.0 to 38.5%) 
Median complication rate: 21.7% 
Not estimable 282 
(5) 
⨁◯◯◯ 
VERY LOW6,7,8 
All complications in the 
MAT group required re-
operation (e.g. arthro-
scopy) except for one 
Transplant failure (single arm) 
Follow up: range 13 months to 120 months; 
assessed with: removal or replacement of 
the graft, or progression to TKA 
Overall transplant failures: 11/248  
(4.4, range 1.7% to 7.7%) 
Median transplant failure rate: 4.5% 
Not estimable 248 
(4) 
⨁◯◯◯ 
VERY LOW4,5,6,9,10 
Failures were defined as 
removal of the graft 
and/or progression  
to TKA 
 
Abbreviations: ADL = activities of daily living; IKDC = International Knee Documentation Committee; KOOS = Knee injury and Osteoarthritis Outcome Score;  
NR = not reported (in study); TKA = total knee arthroplasty. 
 
                                                             
  4 Single-centre trials 
  5 Unclear if all follow-up data were available 
  6 No estimates of the random variability in the reported outcome data 
  7 The method for capturing complications was not adequately reported. It is unclear whether all relevant complications were reported 
  8 Heterogeneity in reported rates across studies 
  9 Thresholds for failure were poorly defined 
10 Heterogeneity in reported rates across studies 
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8 Discussion 
Patients that experience significant meniscal tears, typically due to sporting 
injuries at a younger age, often undergo partial or total meniscectomy for 
symptom control where there is no chance to preserve the meniscus [18-20]. 
However, pain may persist following meniscectomy, which can limit activi-
ties of daily living, cause discomfort, and potentially lead to the progression 
of osteoarthritis and total knee arthroplasty (TKA).  
Meniscal allograft transplantation (MAT) is a potential therapeutic option for 
these patients, which aims to replace the previously removed meniscus and 
restore the capacity of the knee for load-bearing, shock absorption and lubri-
cation. This technique has been researched since the mid 1980’s, and presents 
as one of few treatment options available to patients with post-meniscectomy 
syndrome. 
The aim of this systematic review was to evaluate the safety and effectiveness 
of MAT in comparison to conservative management and no therapy. 
 
Interpretation of findings 
Study quality, validity and overall level of evidence 
Only one comparative study (MAT vs. conservative management) was iden-
tified that could inform the recommendation based on clinical effectiveness 
[23]. This study had a high risk of bias, as discussed in Section 7. Of note, the 
study included patients which the treating surgeon specifically thought would 
benefit from MAT; in doing so, the results may have systematically included 
patients likely to derive a greater benefit from MAT than conservative man-
agement. This study was underpowered to detect a significant difference; 
therefore the results should be interpreted with caution due to the increased 
risk of type 1 error (i.e. accepting a significant effect where none exists). 
The comparative study reported differences between all effectiveness out-
comes that favoured MAT in terms of the direction of effect, but only report-
ed significantly greater differences for KOOS-Pain, KOOS-Composite and 
KOOS-ADL. These results demonstrate that MAT had a significantly greater 
improvement in pain and functions of daily living compared to conservative 
management at 12 months. In contrast, Lysholm, IKDC and KOOS-Sports 
were not significantly different, but did favour MAT in terms of direction of 
effect. The small sample size of the trial limited the precision of the estimates, 
and it is possible that a larger study would bear clinically and statistically sig-
nificant results; however, in the absence of additional information it is un-
known whether these differences are meaningful or not. Moreover, patients 
in both the intervention and control group showed improvements in all effec-
tiveness-related outcomes. 
Although single arm studies were not formally included to evaluate effective-
ness, we extracted outcomes for narrative comparison with the results of the 
cohort study. Interestingly, data on the efficacy outcomes demonstrated con-
flicting results regarding improvements in pain scores, function scores, and 
quality of life scores. Further, these results were often confounded by con-
comitant procedures, and limited by low precision due to small sample sizes. 
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Regarding the safety of MAT, complications were reported poorly in all of 
the included studies. Based on the quality and reporting of the comparative 
study, the additional risks associated with MAT in comparison to conserva-
tive management are highly unclear. Furthermore, due to the risk of bias, 
and variable nature of follow-ups reported in the single arm trials, the re-
sults for graft failure and progression to TKA are subject to substantial un-
certainty. 
The results of this present review are supplemented by two recent, independ-
ent systematic reviews of MAT [61, 62]. One review reported high, but vari-
able failure rates (mean 18.7%, range from 0.0% to 45.3%), and reoperation 
rates for MAT (mean 31.3%, range from 0.0% to 45.3%) [61]. However, this 
review included retrospective studies, and defined failure as poor post-oper-
ative knee function, whereas we considered failure to be related to graft re-
moval or the need for TKA [61]. The second review investigated MAT with or 
without concomitant surgeries, and found no significant difference in relation 
to patient-reported outcomes. The review could not draw reliable conclusions 
on complications, reoperations, survivorship or failure rates on due to insuf-
ficient data [62].  
 
Relevance of the outcomes assessed  
to the potential patient-relevant benefits 
The effectiveness outcomes included in this review directly measured the im-
pact of MAT on disease-related outcomes of pain, function and quality of life. 
The main effectiveness endpoints, KOOS, IKDC, Lysholm, were valid, and 
measured and reported in a consistent way. However, two of these outcomes 
are measured with patient-completed questionnaires, which involve a level 
of subjectiveness. Unfortunately, it is not possible to blind patients to their 
treatment allocation when comparing MAT to conservative management; but 
it is possible to blind investigators that administer other questionnaires such 
as Lysholm, Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) and Tegner activity scores [57]. The applicability of the included 
studies, including population, interventions, comparators and outcomes, is 
outlined in the Appendices (Table A-5). 
 
Evidence gaps and ongoing studies 
Despite the relatively long history of research conducted on MAT [30, 31], 
only one comparative study has compared MAT with the closest eligible in-
tervention – conservative management. In the absence of more comparative 
data, it is difficult to properly understand the benefits associated with MAT. 
Single arm trials do not provide sufficient evidence to demonstrate a clinical 
benefit of MAT. Indeed, recent systematic reviews are now advocating that 
comparative trials should be conducted [63].  
In addition, there are no adequate registered ongoing trials that are compar-
ing MAT with conservative management or even no therapy. Prospective, ran-
domised controlled trials comparing MAT to the standard of care, with at 
least 50 patients in each treatment arm, are needed to adequately inform the 
relative effectiveness of MAT [23]. 
 
Komplikationen in  
allen Studien eher 
dürftig berichtet 
Ergebnisse vorliegender 
Bericht durch  
2 existierende Berichte 
unterstützt 
Endpunkte zu 
Wirksamkeit zwar 
konsistent gemessen, 
aber zum Teil äußerst 
subjektiv 
große Lücken in  
Evidenz 
keine adäquaten 
laufenden Studien 
Discussion 
LBI-HTA | 2018 41 
Limitations in the report 
The results of this review should be interpreted in light of the limitations. 
First, we only included case series with more than 40 patients to evaluate the 
safety of MAT. This may have systematically excluded relevant studies with 
smaller samples, and as such may have excluded case studies that report rare 
adverse events. 
Second, we only included prospective studies, which excluded several large re-
trospective studies; however, retrospective studies are prone to internal validi-
ty concerns due to the limited information on or adjustment for confounding 
factors, selective recruitment of patients, and retrospective measurement of 
relevant outcomes. 
 
Conclusion 
In the absence of comparative data with long-term follow-up, it is difficult to 
properly understand the relative risks and benefits of MAT compared to con-
servative management (or even no therapy). Furthermore, the identified sin-
gle-arm trials were subject to small sample sizes, confounding by concomitant 
procedures, varied techniques used to secure allografts, and prior procedures. 
In consideration of these points, the comparative safety and effectiveness of 
MAT for the treatment of post-meniscectomy syndrome are highly uncertain. 
 
ausschließlich  
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als 40 PatientInnen 
ausschließlich 
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erlaubt keine 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
 The inclusion in the catalogue of benefits is currently not recommended. 
X The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that the assessed technology, 
MAT, is more effective and equally safe compared to the main comparator, 
conservative management. Furthermore, there was no evidence identified com-
paring MAT with no therapy. 
New study results from comparative studies, with a minimum of 50 patients 
in each treatment arm, and with longer-term follow-up may change the rec-
ommendation; however, at this time there are currently only two ongoing tri-
als of MAT, both of which are single arm trials. Therefore, the recommenda-
tion to fund MAT is unlikely to change on the basis of upcoming evidence. 
On the basis of the limited evidence demonstrating a benefit of MAT rela-
tive to the main comparator, as well as the lack of ongoing trials, inclusion in 
the catalogue is not recommended. 
 
 
Empfehlungsschema 
keine ausreichend 
robuste Evidenz 
Studien mit mehr 
PatientInnen + längerer 
Nachbeobachtung 
nötig, derzeit keine 
entsprechenden 
laufenden Studien 
 
Aufnahme  
nicht empfohlen 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Meniscal allograft transplantation (MAT) for patients with post-meniscectomy syndrome: Results from observational studies 
Author, year Smith 2018 [23] Abat 2013 [51] Dirisamer 2012 [58] 
Kempshall 2015 [54] 
(Parkinson 2016 [55]) Cole 2006 [52] LaPrade 2010 [53] 
Country United Kingdom Spain Germany United Kingdom United States United States 
Sponsor Arthritis Research UK None None None None None 
Intervention MAT with soft tissue 
fixation 
MAT with suture-only 
or bony fixation  
MAT with bone block 
and/or soft tissue fixation 
for lateral, and soft 
tissue fixation for medial  
MAT with soft tissue 
fixation 
MAT with bone plug 
fixation 
MAT with bone plug 
fixation 
Comparator Physiotherapy (including 
quadriceps control + 
strength and core strength-
ening programme for 
minimum 3 months) 
None None None None None 
Study design Prospective cohort 
study with nested RCT11 
Prospective case series12 Prospective case series Prospective case series Prospective case series Prospective case series 
Number of pts, n Randomised: 10 vs 11 
Non-randomised: 6 vs 9 
88 (88 menisci) 80 (81 menisci) 60 (60 menisci)13 40 (45 menisci) 40 (40 menisci) 
Inclusion criteria Age 16-50, post-
meniscectomy syndrome, 
surgeon believes patient 
may benefit from MAT 
Post-meniscectomy 
syndrome 
Post-meniscectomy 
syndrome 
Age < 50 years, post-
meniscectomy 
syndrome 
Post-meniscectomy 
syndrome, well-preserved 
articular cartilage 
(Grade 0-II), normal 
knee alignment, stable 
joint (realignable + 
stabilisable joints by 
concomitant procedure 
were also included) 
Post-meniscectomy 
syndrome 
                                                             
11 A parallel group of patients that chose their treatment allocation was included in order to improve recruitment and external validity to “real world” patients. 
12 Study compared MAT with suture fixation and bony fixation. For this review, both study groups were combined into a single (MAT) arm.  
13 Only data from patients with good articular cartilage were extracted for this review. Data from 39 patients with severe cartilage damage were not extracted. 
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Author, year Smith 2018 [23] Abat 2013 [51] Dirisamer 2012 [58] 
Kempshall 2015 [54] 
(Parkinson 2016 [55]) Cole 2006 [52] LaPrade 2010 [53] 
Exclusion criteria Previous cartilage 
modifying procedures 
(e.g. autologous chondro-
cyte implantation), 
significant exposed 
subchondral bone due to 
arthritis, concomitant 
ligament stabilisation, 
contraindication to 
anaesthetic, inability to 
adhere to trial procedures 
Ahlbäck greater  
than Grade II14, 
malalignment (defined 
as above 5° varus 
alignment, and above  
7° valgus alignment) 
NR Inflammatory arthritis, 
advanced joint arthrosis 
in compartments 
distinct from the 
recipient compartment 
Severe arthritic change 
(defined as more than 
isolated Outerbridge 
Grade III changes),15 
femoral condyle or tibial 
flattening, subchondral 
sclerosis 
Patients with more than 
small localised areas of 
Outerbridge Grade IV 
chondromalacia, Grade 
IV “kissing lesions” of 
affected tibiofemoral 
surfaces 
Postoperative 
treatment/ 
rehabilitation 
Physiotherapy 
rehabilitation included 
hinged knee brace, 
crutches and toe touch 
weight bearing for  
6 weeks, cycling after  
6 weeks, strength 
training after 12 weeks. 
Rehabilitation included 
partial weight bearing 
with a knee immobilizer 
after 3 weeks and full 
weight bearing after  
6 weeks. Physiotherapy 
protocols were not 
described. 
NR Personalised physio-
therapy rehabilitation 
included limited weight 
bearing for 6 weeks, 
weight bearing and 
strength training from  
6 weeks, and sport-
specific rehabilitation 
from 6 months 
Rehabilitation included 
immediate weight 
bearing with crutches 
and hinged knee brace 
up to 6 weeks, jogging 
allowed at 12 weeks 
Rehabilitation included 
knee brace, daily 325 mg 
aspirin, quadriceps and 
straight leg exercises for 
up to 6 weeks, weight 
bearing exercise after  
6 weeks, full low-impact 
activity from  
6 to 9 months 
Number of prior 
surgeries per patient,  
n (range) 
NR Mean 1.69 NR NR Mean 2.7 (1 to 6) All patients had under-
gone at least 1 prior 
ipsilateral knee surgery 
Patients with 
concomitant 
interventions, n (%) 
3 (18.8) vs 7 (0.0)16  37 (42.0)17 40 (50.5)18 21 (35.0)19 19 (47.5)20 21 (50.0)21 
                                                             
14 Ahlbäck classification is a measure of osteoarthritis progression in the knee joint, with Grade I representing joint space narrowing of less than 3mm,  
and Grade V representing severe bone attrition of more than 10mm. 
15 Outerbridge classification of 0 represents normal cartilage, Grade II represents a partial thickness defect with fissures on the surface that do not reach subchondral bone  
or exceed 1.5 cm in diameter. 
16 Concomitant interventions included 2 high tibial osteotomies and 1 distal femoral osteotomy in the MAT group, and 7 knee braces in the physiotherapy group. 
17 Concomitant interventions included 18 ACL reconstruction, 15 microfracture, 9 chondral shaving, 3 hardware removal, 2 cartilage repair. 
18 The reported sum of concomitant and isolated interventions was 82 procedures. Thus, double-counting was suspected.  
Concomitant interventions included 15 ACL reconstructions and 23 high tibial osteotomies, 1 distal femoral osteotomy and one identifiable intervention. 
19 Concomitant interventions included 5 distal femoral osteotomy, 6 high tibial osteotomy, 6 revision ACL reconstruction, 1 meniscal repair (other compartment),  
2 micro fracture, 2 Trufit Plug. 
20 Concomitant interventions included 3 osteochondral allografts, 3 osteochondral autografts, 2 microfractures, 2 osteochondritis dissecans fixations,  
1 autologous chondrocyte implantation, 1 chondral debridement, 6 concurrent ligament reconstructions, 1 osteotomy. 
21 Concomitant procedures included 10 ACL reconstruction, 3 distal femoral osteotomy, 5 microfracture, 4 hardware removal, 3 osteoarticular allograft.  
Note: Some patients had more than one concomitant procedure. 
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Author, year Smith 2018 [23] Abat 2013 [51] Dirisamer 2012 [58] 
Kempshall 2015 [54] 
(Parkinson 2016 [55]) Cole 2006 [52] LaPrade 2010 [53] 
Age of patients,  
years (range) 
Mean 29 (NR) vs 27 (NR) Mean 37 (15 to 51) Mean 40 (14 to 57) Median 27 (16 to 48) Mean 31 (16 to 48) Mean 25 (20 to 40) 
Time since menis-
cectomy, years (range) 
8.2 (NR) vs 7.6 (NR) Mean 13.89 (NR) NR Mean 6.9 (1.0 to 25.4) NR Mean 4.5 (1 to 26) 
Medial:lateral, n (%) 2 (12.5) : 14 (87.5) vs 6 
(30.0) : 14 (70.0) 
40 (45.5) : 48 (54.5) 55 (67.9) : 26 (32.1) 14 (23.3) : 46 (76.7) 25 (62.5) : 19 (37.5) 19 (47.5) : 21 (52.5) 
Clinical classification NR Ahlbäck Grade I-II  NR Up to ICRS Grade 3b22 Outerbridge Grade 0-II Outerbridge Grade 0-IV 
Type of transplant(s) Fresh-frozen, non-
irradiated allografts 
Fresh-frozen (-80°C), 
non-irradiated,  
non-antigen-matched 
allografts 
Fresh-frozen allografts Fresh-frozen, non-
irradiated allografts 
Cryopreserved or fresh-
frozen, non-irradiated 
allografts 
Non-irradiated, 
cryopreserved  
(-20°C short term, -80°C 
long term) allografts 
Characteristics of 
surgeon(s) 
Senior surgeons familiar 
with technique, number 
of surgeons NR 
Single surgeon (senior) Two surgeons Single surgeon Single surgeon Single surgeon (senior) 
Sex, n male (%)  13 (81.2) vs. 13 (65) 56 (64.0) NR 40 (66.7) 22 (61.1) 27 (67.5) 
Follow-up,  
months (range) 
12 vs. 12 Mean 60 (30 to 120) Mean 45.4 Mean 35 (13 to 109) Mean 33.5 (24 to 57) Mean 30 (22 to 48) 
Loss to follow-up, n (%) 3 (18.8) vs 2 (10.0) 0 (0.0) 19 (24.8) at 12 months 0 (0.0)23 1 (2.5) 6 (15.0) 
Efficacy Outcomes 
Mean pain scores 
(VAS: lower scores 
indicate lower pain) 
(KOOS: higher scores 
indicate lower pain) 
KOOS – Pain 
Mean difference in 
change after 12 months: 
15.1 (95% CI 2.4 to 27.8, 
p=0.021) 
VAS 
Baseline: 6.59 
Follow up (mean 60 
months): 1.13 
Mean change: -5.46, 
p=NR 
NR KOOS – Pain 
Baseline: 61.3 
Follow-up (24 months): 
83.6 
Change: 22.3, p<0.001 
KOOS – Pain 
Baseline: 60.2 
Follow-up  
(mean 33.5 months): 77.2 
Change: 17, p<0.05 
VAS 
Baseline: 5.8 
Follow-up  
(mean 33.5 months): 3.2 
Mean change: -2.6, p<0.05 
NR 
Function scores 
(higher scores indicate 
better function) 
Lysholm 
Mean difference in 
change after 12 months: 
7.3 (95% CI -4.5 to 19.1, 
p=0.22) 
Lysholm 
Baseline: 64.46 
Last follow-up (mean  
60 months): 90.23 
Mean change: 26.76, 
p>0.05 
Lysholm 
Baseline: 43 
Last follow-up (mean  
48 months): 6924 
Mean change: 26,  
p=NR 
Lysholm 
Baseline: 58.6 
Follow-up (24 months): 
80.2  
Mean change: 21.6, 
p<0.001 
Lysholm 
Baseline: 52.4 
Follow-up (mean  
33.5 months): 71.6 
Mean Change: 19.2, 
p<0.05 
Cincinnatti knee rating 
Baseline: 53.7 
Follow-up (mean  
30 months): 75.3 
Mean change: 21.6, 
p<0.001 
                                                             
22 International Cartilage Repair Society (ICSR) cartilage Grade 3b involving less than 1cm2 was defined as “good” cartilage status by the study authors. 
23 Applies for a follow-up of 12 months. 
24 Measured in 31 patients. 
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Author, year Smith 2018 [23] Abat 2013 [51] Dirisamer 2012 [58] 
Kempshall 2015 [54] 
(Parkinson 2016 [55]) Cole 2006 [52] LaPrade 2010 [53] 
Function scores 
(higher scores indicate 
better function) 
(continuation) 
IKDC 
Mean difference in 
change after 12 months: 
8.44 (95% CI -3.6 to 20.5, 
p=0.16) 
KOOS – Composite 
Mean difference in 
change after 12 months: 
11.9 (95% CI 1.1 to 22.7, 
p=0.034) 
KOOS – ADL 
Mean difference in 
change after 12 months: 
18.2 (95% CI 6.0 to 30.5, 
p=0.005) 
KOOS – Sports 
Mean difference in 
change after 12 months: 
14.0 (95% CI -2.7 to 30.8, 
p=0.098) 
Tegner 
Baseline: 3 
Last follow-up (mean  
60 months): 6 
Mean change: 3,  
p>0.05 
Tegner 
Baseline: 4 
Last follow-up (mean  
36 months): 725 
Mean change: 3,  
p=NR 
Tegner 
Baseline: 2 
Follow-up (24 months): 4 
Mean change: 2,  
p<0.05 
IKDC 
Baseline: 43.1 
Follow-up (24 months): 
68.8 
Mean change: 25.7, 
p<0.001 
KOOS – ADL 
Baseline: 71.4 
Follow-up (24 months): 
90.2 
Mean change: 18.8, 
p<0.001 
KOOS – Sports 
Baseline: 30.8 
Follow-up (24 months): 
60.0 
Mean change: 29.2, 
p<0.001 
Tegner 
Baseline: 5 
Follow-up (mean  
33.5 months): 6.5 
Mean change: 1.5, p<0.05 
IKDC 
Baseline: 46.2 
Follow-up (mean  
33.5 months): 64.1 
Mean change: 17.9, 
p<0.05 
KOOS – ADL 
Baseline: 80.1 
Follow-up (mean  
33.5 months): 87.8 
Mean change: 7.8, 
p<0.05 
KOOS – Sports 
Baseline: 30.1  
Follow-up (mean  
33.5 months): 51.6 
Mean change: 21.5, 
p<0.05 
IKDC 
Baseline (mean): 54.3 
Follow-up (mean  
30 months): 72 
Mean change: 17.7, 
p<0.001 
Quality of life scores 
(higher scores indicate 
better health) 
KOOS – QoL 
Mean difference in 
change after 12 months: 
12.6 (95% CI -0.4 to 25.6, 
p=0.058) 
NR NR KOOS – QoL 
Baseline: 28.9 
Follow-up (24 months): 
52.7 
Mean change: 23.8, 
p<0.001 
KOOS – QoL 
Baseline: 27.5 
Follow-up (mean  
33.5 months): 50.4 
Mean change: 23.0, 
p=0.16 
NR 
Return to daily 
activities 
NR NR NR NR NR NR 
Necessity of total joint 
replacement 
NR NR At mean 36 months:  
2 (2.5) 
NR At mean 33.5 months: 
3 (7.5)26 
NR 
Patient satisfaction 
(higher scores indicate 
greater satisfaction) 
NR Mean VAS score at last 
follow-up (mean 60 
months): 3.7 ± 0.3  
(out of 4) 
NR NR Mean VAS score at last 
follow-up (mean 33.5 
months): 7.63 (out of 10) 
75.0% (27/36) were 
completely or mostly 
satisfied with procedure 
at last follow-up  
(mean 33.5 months) 
NR 
                                                             
25 Measured in an unclear number of patients.  
26 Two patients needed a total knee arthroplasty, one patient needed a unicompartmental knee replacement. 
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Author, year Smith 2018 [23] Abat 2013 [51] Dirisamer 2012 [58] 
Kempshall 2015 [54] 
(Parkinson 2016 [55]) Cole 2006 [52] LaPrade 2010 [53] 
Safety Outcomes 
Complications, n (%) 5 (38.5) vs 1 (5.6) 
MAT: complications not 
adequately defined 
Physio: 1 thigh bruising 
due to knee brace 
20 (22.7) 
5 arthrofibrosis 
4 infection 
11 meniscus tear 
12 (19.7)27 
6 MAT re-fixations 
1 partial meniscectomy 
1 MAT removal 
1 new MAT 
2 joint replacements 
1 post-surgical infection 
18 (30.0): 
8 meniscus tear,  
1 haematoma,  
1 common peroneal 
nerve palsy,  
4 painful suture removal, 
4 second look scope 
0 (0.0) 7 (20.6): 
1 infection,  
1 low-Grade synovitis,  
5 meniscal tears, 
(Average 24 months  
to re-injury) 
Transplant failure, n (%) NR 5 (5.7)28 2 (3.3)29 1 (1.7)30 within 2 years 
(2-year survival: 97.9%) 
3 (7.7)31 NR 
Time to failure, 
months (range) 
NR NR NR NR Mean 15 (9 to 21) NR 
Re-operation, n (%)  4 (30.8)32 vs N/A 20 (22.7)33 12 (19.7)34 18 (30.0)35 3 (7.7)36 7 (20.6)37 
Procedure-related 
mortality, n (%)  
0 (0.0) 0 (0.0) NR 0 (0.0) 0 (0.0) 0 (0.0) 
Abbreviations: ADL = activities of daily living; CT = (non-randomised) controlled trial; ICRS = International Cartilage Repair Society; IKDC = International Knee Documentation Committee; 
KOOS = Knee injury and Osteoarthritis Outcome Score; MAT = meniscal allograft transplantation; N/A = not applicable; NR = not reported; QoL = quality of life; RCT = randomised 
controlled trial; VAS = visual analogue scale. 
 
                                                             
27 Complications were exclusively stated in terms of re-operations.  
28 Failure was defined as removal of the graft. 
29 Failure was defined as the removal or replacement of the graft. Joint replacements were not counted. 
30 Failure was defined as removal of the graft or progression to arthroplasty. 
31 Failure was defined as progression to arthroplasty. Four additional patients had “clinical failure” due to worsening IKDC scores,  
but did not have the graft removed or joint replaced. 
32 Four patients had subsequent arthroscopy. 
33 All complications required a secondary operation, including 5 arthroscopic arthrolysis, 4 arthroscopic lavage, and 6 MAT re-fixation, and 5 MAT removals. 
34 All complications required a secondary operation, including 6 MAT re-fixations, 1 partial meniscectomy, 1 MAT removal, 1 new MAT, 2 joint replacements, 1 post-surgical infection.  
35 All complications required a secondary operation, including 4 second-look arthroscopies, 6 MAT re-fixation, 1 MAT trim, and 1 MAT removal. 
36 Three patients required total knee replacement. 
37 Five patients required meniscectomy to treat a meniscal tear, 1 patient required arthroscopic synovectomy to treat low-grade synovitis,  
1 arthroscopic irrigation and debridement of infection. 
  
M
en
iscal allo
graft tran
splan
tatio
n
 fo
r po
st-m
en
iscecto
m
y syn
drom
e 
54
 
LB
I-H
T
A
| 20
18
 
Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. Disagreements were settled via consensus. The ROBNS-I tool was used to 
evaluate the risk of bias in the non-randomised comparative study [59]. A more detailed description of the criteria used to assess the internal validity of the non-
randomised comparative trial can be found from the Cochrane Collaboration [59], and in the Guidelines of EUnetHTA [64]. Single arm studies were appraised 
according to the Institute of Health Economics (IHE) appraisal tool for case series studies [14]. 
Table A-2: Risk of bias – study level (non – randomised studies comparing meniscus allograft transplantation versus physiotherapy), see [59] 
Study  
reference/ID 
Bias due to 
confounding 
Bias selection of 
participants into  
the study 
Bias in 
measurement  
of intervention 
Bias due to departures 
from intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement 
of outcomes 
Bias in selection 
of the reported 
results 
Overall 
Bias Comments 
Smith 2018 [23]  
(Smith 2016 [65])38 
Serious39 Moderate40 Low Moderate41 Serious42 Serious43 Serious44 Serious -  
 
 
                                                             
38 Additional details about the study design were provided in the RCT protocol [65], therefore, both publications were used to assess the risk of bias.  
39 Distribution of key confounding factors (e.g. subsequent procedures) were not comprehensively evaluated or adjusted for in the analysis. 
40 A small number of patients (n=4) were excluded because the treating surgeon did not think they would benefit from the intervention, no justification was provided. 
41 Inadequate information was provided about the use, or not, of subsequent procedures and interventions, or adherence to post-operative physiotherapy in the MAT group. 
42 There was a large proportion of missing data, which is likely to have affected the results. 
43 Research associates that assessed post-operative outcomes and conducted the analyses were blinded to the treatment allocation; however, patients could not be blinded  
to the intervention. As the outcomes are subjective, they are likely to be influenced by knowledge of the treatment allocation. 
44 The primary outcomes of interest for this review were reported in accordance with the protocol; Additional outcomes, including cartilage thickness and loss, were defined  
in the protocol but not reported in the clinical trial publication. Complications were poorly defined in the protocol, and poorly reported in the trial publication. 
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Table A-3: Risk of bias – study level (case series), see [14] 
Study reference/ID 
Abat  
2013 [51] 
Dirisamer  
2012 [58] 
Kempshall 2015 [54] 
(Parkinson 2016 [55]) 
Cole  
2006 [52] 
LaPrade 
2010 [53] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction,  
or methods section? 
Yes No Yes Yes Yes 
Study population 
2. Are the characteristics of the participants included in the study described? Yes No45 Yes Yes Yes 
3. Were the cases collected in more than one centre? No No No No No 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit  
and appropriate? 
Yes No46 Yes Yes Yes 
5. Were participants recruited consecutively? Yes Yes Yes Yes Yes 
6. Did participants enter the study at similar point in the disease? Yes Unclear47 Yes Yes No 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? Yes Yes Yes Yes Yes 
8. Were additional interventions (co-interventions) clearly reported in the study? Yes Yes Yes Yes Yes 
Outcome measures 
9. Are the outcome measures clearly defined in the introduction or methods section? Yes No48 Yes Yes Yes 
10. Were relevant outcomes appropriately measured with objective and/or subjective methods? No49 No No50 Yes Yes 
11. Were outcomes measured before and after intervention? Yes Yes Yes Yes Yes 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? No No51 Yes Yes Yes 
Results and Conclusions 
13. Was the length of follow-up reported? Yes Yes Yes Yes Yes 
14. Was the loss to follow-up reported? Yes Yes No52 Yes Yes 
15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? Yes No Yes No No 
16. Are adverse events reported? Yes Yes Yes Yes Yes 
                                                             
45 There were several characteristics missing (e.g. sex, information on postoperative treatment and number of prior surgeries). 
46 Exclusion criteria were not stated. 
47 Clinical classification not stated. 
48 Study did not provide a clear section on methods that described outcomes measures. 
49 The method for capturing complications was not adequately reported. It is unclear whether all relevant complications were reported.  
50 The method for capturing complications was not adequately reported. It is unclear whether all relevant complications were reported.  
51 Study did not conduct statistical tests. 
52 It is not clear if all data were available for the 2-year follow-up. 
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Study reference/ID 
Abat  
2013 [51] 
Dirisamer  
2012 [58] 
Kempshall 2015 [54] 
(Parkinson 2016 [55]) 
Cole  
2006 [52] 
LaPrade 
2010 [53] 
17. Are the conclusions of the study supported by results? Yes No No No Yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? No No Yes No No 
Overall risk of bias Moderate Serious Moderate Moderate Moderate 
 
Table A-4: Evidence profile: efficacy and safety of meniscal allograft transplantation compared to conservative management in patients with post-meniscectomy syndrome 
Quality assessment 
Summary of findings 
Number of patients Effect 
Quality 
Number  
of studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations MAT 
Conservative 
management 
Relative 
(95% CI) Absolute (95% CI) 
Efficacy 
Pain: change in pain score (follow up: 12 months; assessed with: KOOS – Pain Subscale; Scale from: 0 to 100 (better)) 
1  observational 
study
 53 
serious 54 N/A  
(only one trial) 
not serious  serious 55 none 13 18  - MD 15.1 points higher 
(2.4 higher to 27.8 higher)  
⨁◯◯◯ 
VERY LOW 
Function: Change in function score (follow up: 12 months; assessed with: Lysholm; Scale from: 0 to 100 (better)) 
1  observational 
study 53 
serious54 N/A  
(only one trial) 
not serious  serious 55 none 13 18 -  MD 7.3 points higher 
(4.5 lower to 19.1 higher)  
⨁◯◯◯ 
VERY LOW 
Function: Change in function score (follow up: 12 months; assessed with: IKDC; Scale from: 0 to 100 (better)) 
1  observational 
study 53 
serious 54 N/A  
(only one trial) 
not serious  serious 55 none 13 18 -  MD 8.44 points higher 
(3.6 lower to 20.5 higher)  
⨁◯◯◯ 
VERY LOW 
Function: Change in function score (follow up: 12; assessed with: KOOS-Composite; Scale from: 0 to 100 (better)) 
1  observational 
study 53 
serious 54 N/A  
(only one trial) 
not serious  serious 55 none 13 18 -  MD 11.9 points higher 
(1.1 higher to 22.7 higher)  
⨁◯◯◯ 
VERY LOW 
Function: Change in function score (follow up: 12; assessed with: KOOS-ADL; Scale from: 0 to 100 (better)) 
1  observational 
study 53 
serious 54 N/A  
(only one trial) 
not serious  serious 55 none 13 18 -  MD 18.2 points higher 
(6 higher to 30.5 higher)  
⨁◯◯◯ 
VERY LOW 
Function: Change in function score (follow up: 12; assessed with: KOOS-Sports; Scale from: 0 to 100 (better)) 
1  observational 
study 53 
serious 54 not serious  not serious  serious 55 none 13 18 -  MD 14 points higher 
(2.7 lower to 30.8 higher)  
⨁◯◯◯ 
VERY LOW 
Necessity of total joint replacement: not measured 
                                                             
53 Prospective cohort study with nested RCT 
54 There was a serious risk of bias due to possible confounding, missing data, and the use of un-blinded patient-reported outcome measures 
55 Sample size of the prospective cohort study with nested RCT is below optimal information size. Conventional sample size calculation required 50 patients in each study arm 
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Quality assessment 
Summary of findings 
Number of patients Effect 
Quality 
Number  
of studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations MAT 
Conservative 
management 
Relative 
(95% CI) Absolute (95% CI) 
Safety 
Complications (follow up: 12 months) 
1  observational 
study 53 
serious 
54,56 
N/A  
(only one trial)  
not serious  serious 55,57 none 5/13 
(38.5%)  
1/18 (5.6%)  RR 6.92  
(0.91 lower to 
52.45 higher)58 
329 more per 1,000 (from 
5 fewer to 1,000 more) 
⨁◯◯◯ 
VERY LOW 
Complications (follow up: range 13 months to 120 months) 
5 observational 
studies 59 
serious 
56,60,61 
serious 62 not serious  serious 57 none Overall complications: 57/282 (20.2%, range 0.0 to 38.5%) 
Median complication rate: 21.7% 
⨁◯◯◯ 
VERY LOW 
Transplant failure (follow up: range 13 months to 120 months; assessed with: removal or replacement of the graft, or progression to TKA) 
4  observational 
studies 63 
Serious 
61,62,64 
not serious  not serious  serious 57,65 none Overall transplant failures: 11/248 (4.4, range 1.7% to 7.7%) 
Median transplant failure rate: 4.5% 
⨁◯◯◯ 
VERY LOW 
Abbreviations: ADL = activities of daily living; IKDC = International Knee Documentation Committee; KOOS = Knee injury and Osteoarthritis Outcome Score; N/A = not applicable 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
                                                             
56 The method for capturing complications was not adequately reported. It is unclear whether all relevant complications were reported 
57 No estimates of the random variability in the reported outcome data 
58 Calculated manually by using ‘MedCalc’ (http://www.medcalc.org/calc/relative_risk.php) 
59 5 case series 
60 Single-centre trials (applies for single-arm studies/case series) 
61 Unclear if all follow-up data were available 
62 Heterogeneity in reported rates across studies 
63 4 case series 
64 Thresholds for failure were poorly defined 
65 Low event rates and small sample sizes 
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Applicability table 
Table A-5: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The broad patient characteristics in relation to age, sex, cartilage status and indication  
(i.e. post-meniscectomy syndrome) were relatively homogenous across studies. However, there  
was considerable variation in time from meniscectomy to surgery for MAT (meniscal allograft 
transplantation), and the proportion of medial or lateral menisci transplanted. Overall, the populations 
in the included studies broadly reflect the target population in clinical practice, i.e. mostly young 
patients (mean age 33, range 14-57), with post-meniscectomy syndrome and no significant chondral 
defects (i.e. Outerbridge Grade 0-II, Ahlbäck Grade I). 
Intervention The intervention was conducted via arthroscopy in all but one study, whereby the authors used  
a combination of arthroscopy and mini-arthrotomy. Allografts were predominantly non-irradiated 
fresh-frozen; a minority of allografts across the included studies were cryopreserved. The technique 
used to fix the allografts differed between studies (bone-plug or soft-tissue). All patients received 
post-operative rehabilitation following surgery. There was significant heterogeneity in the number 
and type of concomitant interventions conducted in the observational trials. It is unclear how reflective 
these concomitant interventions are of an Austrian post-meniscectomy population. 
Comparators International guidelines on the recommended use of MAT are not currently available. The primary 
purpose of meniscal allograft transplant in the context of post-meniscectomy syndrome is symptom 
control, and to delay the need for total knee arthroplasty. In this context, the most suitable 
alternatives to MAT are conventional management or no treatment. 
The comparator used in the observational trial was personalised physiotherapy, including quadriceps 
control and core strength training for a minimum of three months. Symptomatic management, 
including knee injections, non-steroidal anti inflammatory drugs and other pain medication were 
not described. Conservative management protocols to treat post-meniscectomy syndrome are often 
based on specific patient requirements. Therefore, the comparator is likely to reflect the likely 
physiotherapy strategy for Austrian patients. 
Outcomes The comparative study reported most of the critical/important clinical outcomes, with the exception 
of graft failure and necessity of total joint replacement. It is possible that there were no reported 
cases of either outcome due to the short follow-up period (12 months), however this was not stated. 
Some safety outcomes, such as procedure-related complications, were not recorded in a 
comprehensive or consistent way. 
Follow-up times were reported variably. Efficay outcomes from the comparative study were reported 
at 12 months, therefore cannot inform the long-term efficacy of MAT in the proposed population. 
The single-arm trials reported safety outcomes at an average of 44 months (range 13 to 120). 
Setting The included comparative study was conducted in a single centre in the United Kingdom (UK). The 
allografts used in the study were supplied by the National Health Service Blood and Transplant (UK), 
or JRF Ortho (United States). The single arm studies included for safety outcomes were conducted 
in Spain, Germany, the United Kingdom, and the United States. All studies were conducted in teaching 
hospitals, by orthopaedic surgeons. The settings in which MAT was conducted in the included trials 
is largely reflective of the intended use of the procedure in clinical practice. 
Abbreviations: MAT = meniscal allograft transplantation; UK = United Kingdom. 
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List of ongoing randomised controlled trials 
Table A-6: List of ongoing trials of meniscus allograft transplantation 
Identifier/ 
Trial name Patient population Intervention Comparison 
Primary 
Outcome 
Primary 
completion date Sponsor 
NCT01059409 Patients with post-
meniscectomy 
Estimated 
enrollment = 120 
participants 
MAT None  
(case series 
with  
120 patients) 
“Function” 
Subscale in the 
Koos Scale 
September 2017 Assistance 
Publique – 
Hôpitaux 
de Paris 
NTR6630 Patients with post-
meniscectomised, 
symptomatic knee 
Estimated 
enrollment = 119 
participants 
MAT None  
(case series 
with  
119 patients) 
Overview of 
patients' 
previous 
operations, 
patients' 
satisfaction 
October 2017 Haaglanden 
Medical 
Center, The 
Hague 
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Literature search strategies 
Search strategy for The Cochrane Library 
Search Date: 22/12/2017 
ID Search 
#1 meniscectom* (Word variations have been searched) 
#2 meniscectom* (Word variations have been searched) 
#3 MeSH descriptor: [Tibial Meniscus Injuries] explode all trees 
#4 MeSH descriptor: [Meniscus] explode all trees and with qualifier(s): [Injuries – IN, Surgery – SU] 
#5 MeSH descriptor: [Menisci, Tibial] explode all trees and with qualifier(s): [Surgery – SU] 
#6 post-meniscectom* near syndrome* (Word variations have been searched) 
#7 "postmeniscectomy" (Word variations have been searched) 
#8 "post-meniscectomy" (Word variations have been searched) 
#9 menisc* near (deficien* or insufficien*) (Word variations have been searched) 
#10 symptomatic near menisc* (Word variations have been searched) 
#11 "joint line pain*" (Word variations have been searched) 
#12 allogenic menisc* transplant* (Word variations have been searched) 
#13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 
#14 MeSH descriptor: [Allografts] explode all trees 
#15 MeSH descriptor: [Composite Tissue Allografts] explode all trees 
#16 MeSH descriptor: [Transplantation, Homologous] explode all trees 
#17 allograft* or allogeneic or homograft* (Word variations have been searched) 
#18 #14 or #15 or #16 or #17 
#19 MeSH descriptor: [Menisci, Tibial] explode all trees 
#20 MeSH descriptor: [Meniscus] explode all trees 
#21 menisc* (Word variations have been searched) 
#22 MeSH descriptor: [Knee] explode all trees 
#23 knee* (Word variations have been searched) 
#24 #19 or #20 or #21 or #22 or #23 
#25 #18 and #24v 
#26 MeSH descriptor: [Meniscus] explode all trees and with qualifier(s): [Transplantation – TR] 
#27 MeSH descriptor: [Menisci, Tibial] explode all trees and with qualifier(s): [Transplantation – TR] 
#28 MAT:ti,ab,kw (Word variations have been searched) 
#29 #25 or #26 or #27 or #28 
#30 #13 and #29 
#31 (menisc* or knee*) near (allograft* or allogeneic or homograft*) (Word variations have been searched) 
#32 Menisc* Allograft* Transplant* (Word variations have been searched) 
#33 #30 or #31 or #32 
Total: 85 Hits 
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Search strategy for Ovid Medline 
Database: Ovid MEDLINE(R) <1946 to December Week 2 2017>, Ovid MEDLINE(R) Epub Ahead of Print 
<December 21, 2017>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 21, 2017>, Ovid 
MEDLINE(R) Daily Update <December 21, 2017> 
Search Strategy: 
1 menis#e#tom*.mp. (3114) 
2 (menisc* adj5 remov*).mp. (353) 
3 exp Tibial Meniscus Injuries/ (4465) 
4 exp *Meniscus/in, su [Injuries, Surgery] (2317) 
5 exp *Menisci, Tibial/in, su [Injuries, Surgery] (2295) 
6 post*menis#e#tom* syndrome*.mp. (4) 
7 post?menis#e#tom*.mp. (70) 
8 (menisc* adj3 (deficien* or insufficien*)).mp. (183) 
9  (symptomatic adj3 menisc*).mp. (241) 
10 joint line pain*.mp. (47) 
11 allogenic menisc* transplant*.mp. (4) 
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (7515) 
13 exp Allografts/ (6004) 
14 exp Composite Tissue Allografts/ (124) 
15 exp Transplantation, Homologous/ (87630) 
16 (allograft* or allogeneic or homograft*).mp. (126772) 
17 13 or 14 or 15 or 16 (170020) 
18 exp Menisci, Tibial/ (7400) 
19 exp Meniscus/ (7483) 
20 menisc*.mp. (17733) 
21 exp Knee/ (13955) 
22 knee*.mp. (162462) 
23 18 or 19 or 20 or 21 or 22 (167769) 
24 17 and 23 (3430) 
25 ((menisc* or knee*) adj5 (allograft* or allogeneic or homograft*)).mp. (938) 
26 Menisc* Allograft* Transplant*.mp. (299) 
27 MAT.ti,ab. (8475) 
28 exp *Meniscus/tr [Transplantation] (397) 
29 exp *Menisci, Tibial/tr [Transplantation] (394) 
30 24 or 25 or 26 or 27 or 28 or 29 (11868) 
31 12 and 30 (459) 
32 remove duplicates from 31 (387) 
Search date: 22/12/2017 
 
  
Meniscal allograft transplantation for post-meniscectomy syndrome 
62 LBI-HTA | 2018 
Search strategy for Embase 
No. Query Results Results Date 
#27 #10 AND #26 482 22 Dec 2017 
#26 #21 OR #22 OR #23 OR #24 OR #25 13,500 22 Dec 2017 
#25 'meniscal transplantation'/exp 349 22 Dec 2017 
#24 mat:ti,ab 9,228 22 Dec 2017 
#23 'menisc* allograft* transplant*'   304 22 Dec 2017 
#22 (menisc* OR knee*) NEAR/5 (allograft* OR allogeneic OR homograft*) 1,102 22 Dec 2017 
#21 #15 AND #20 4,268 22 Dec 2017 
#20 #16 OR #17 OR #18 OR #19 206,536 22 Dec 2017 
#19 knee* 203,416 22 Dec 2017 
#18 'knee'/exp 59,379 22 Dec 2017 
#17 menisc* 20,780 22 Dec 2017 
#16 'knee meniscus'/exp 7,555 22 Dec 2017 
#15 #11 OR #12 OR #13 OR #14 207,882 22 Dec 2017 
#14 allograft* OR allogeneic OR homograft* 184,673 22 Dec 2017 
#13 'allotransplantation'/exp 34,755 22 Dec 2017 
#12 'composite graft'/exp 2,243 22 Dec 2017 
#11 allograft'/exp 36,957 22 Dec 2017 
#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 4,996 22 Dec 2017 
#9 allogenic menisc* transplant*':ti,ab 4 22 Dec 2017 
#8 'joint line pain*':ti,ab 55 22 Dec 2017 
#7 (symptomatic NEAR/3 menisc*):ti,ab 226 22 Dec 2017 
#6 (menisc* NEAR/3 (deficien* OR insufficien*)):ti,ab 196 22 Dec 2017 
#5 post*menis*e*tom*:ti,ab 78 22 Dec 2017 
#4 'post*menis*e*tom* syndrome*':ti,ab 8 22 Dec 2017 
#3 (menisc* NEAR/5 remov*):ti,ab 419 22 Dec 2017 
#2 menis*e*tom*:ti,ab 3,461 22 Dec 2017 
#1 'meniscectomy'/exp 2,922 22 Dec 2017 
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Search strategy for CRD (DARE, NHS-EED, HTA) 
Search Date: 22/12/2017 
#1 MeSH DESCRIPTOR Allografts EXPLODE ALL TREES 
#2 MeSH DESCRIPTOR Composite Tissue Allografts EXPLODE ALL TREES 
#3 MeSH DESCRIPTOR Transplantation, Homologous EXPLODE ALL TREES 
#4 (allograft* OR allogeneic OR homograft*) 
#5 #1 OR #2 OR #3 OR #4 
#6 MeSH DESCRIPTOR Menisci, Tibial EXPLODE ALL TREES 
#7 MeSH DESCRIPTOR Meniscus EXPLODE ALL TREES 
#8 (menisc*) 
#9 MeSH DESCRIPTOR Knee EXPLODE ALL TREES 
#10 (Knee*) 
#11 #6 OR #7 OR #8 OR #9 OR #10 
#12 #5 AND #11 
#13 ((menisc* OR knee*) NEAR (allograft* OR allogeneic OR homograft*)) 
#14 (Menisc* Allograft* Transplant*) 
#15 (MAT) 
#16 MeSH DESCRIPTOR Meniscus EXPLODE ALL TREES WITH QUALIFIER TR 
#17 MeSH DESCRIPTOR Menisci, Tibial EXPLODE ALL TREES WITH QUALIFIER TR 
#18 (post*menis*e*tom*) 
#19 (menisc* NEAR (deficien* or insufficien*)) 
#20 (symptomatic NEAR menisc*) 
#21 (joint line pain*) 
#22 (allogenic menisc* transplant*) 
Total:55 Hits 
 
 
 
  
 
